Abbvie Drug Patent Portfolio
Abbvie owns 73 orange book drugs protected by 513 US patents with Creon having the least patent protection, holding only 1 patent. And Kaletra with maximum patent protection, holding 49 patents. Given below is the list of Abbvie's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11717515 | Treatment of migraine | 22 Dec, 2041 | Active |
| US11857542 | Treatment of migraine | 22 Dec, 2041 | Active |
| US12070450 | Treatment of migraine | 22 Dec, 2041 | Active |
| US12194030 | Treatment of migraine | 22 Dec, 2041 | Active |
| US12090148 | Treatment of migraine | 29 Jul, 2041 | Active |
| US11690845 | Methods of administering elagolix | 27 Aug, 2040 | Active |
| US12251365 | Pharmaceutical formulations for subcutaneous administration | 10 Jun, 2040 | Active |
| US11542239 | Elagolix sodium compositions and processes | 23 Jul, 2039 | Active |
| US10610518 | Presbyopia treatments | 24 Apr, 2039 | Active |
| US11285134 | Presbyopia treatments | 24 Apr, 2039 | Active |
| US12083227 | Solid pharmaceutical formulations for treating endometriosis, uterine fibroids, polycystic ovary syndrome or adenomyosis | 20 Aug, 2038 | Active |
| US12102637 | Pharmaceutical formulations for treating endometriosis, uterine fibroids, polycystic ovary syndrome or adenomyosis | 20 Aug, 2038 | Active |
| US11690854 | Methods of treating heavy menstrual bleeding | 19 Apr, 2038 | Active |
| US11564922 | Methods of treating crohn's disease and ulcerative colitis | 09 Mar, 2038 | Active |
| US11607411 | Methods of treating Crohn's disease and ulcerative colitis | 09 Mar, 2038 | Active |
| US11246866 | Solid pharmaceutical compositions for treating HCV | 24 Dec, 2036 | Active |
| US10202393 | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-α]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof | 17 Oct, 2036 | Active |
| US10344036 | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-#a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-#carboxamide and solid state forms thereof | 17 Oct, 2036 | Active |
| US10519164 | Processes for the preparation of (3S,4R)-3,ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof | 17 Oct, 2036 | Active |
| US10550126 | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof | 17 Oct, 2036 | Active |
| US10597400 | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carb oxamide and solid state forms thereof | 17 Oct, 2036 | Active |
| US10730883 | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof | 17 Oct, 2036 | Active |
| US10981923 | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[l,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof | 17 Oct, 2036 | Active |
| US10981924 | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof | 17 Oct, 2036 | Active |
| US10995095 | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carb oxamide and solid state forms thereof | 17 Oct, 2036 | Active |
| US11186584 | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof | 17 Oct, 2036 | Active |
| US11198697 | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof | 17 Oct, 2036 | Active |
| US11365198 | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof | 17 Oct, 2036 | Active |
| US11512092 | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof | 17 Oct, 2036 | Active |
| US11524964 | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof | 17 Oct, 2036 | Active |
| US11535624 | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-α]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof | 17 Oct, 2036 | Active |
| US11535625 | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof | 17 Oct, 2036 | Active |
| US11535626 | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1 carboxamide and solid state forms thereof | 17 Oct, 2036 | Active |
| US11661425 | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof | 17 Oct, 2036 | Active |
| US11680069 | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof | 17 Oct, 2036 | Active |
| US11718627 | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof | 17 Oct, 2036 | Active |
| US11767326 | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof | 17 Oct, 2036 | Active |
| US11773105 | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]- pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof | 17 Oct, 2036 | Active |
| US11773106 | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof | 17 Oct, 2036 | Active |
| US11780847 | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof | 17 Oct, 2036 | Active |
| US11780848 | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof | 17 Oct, 2036 | Active |
| US11787815 | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof | 17 Oct, 2036 | Active |
| US11795175 | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof | 17 Oct, 2036 | Active |
| US11976077 | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-α]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms therof | 17 Oct, 2036 | Active |
| US11993605 | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof | 17 Oct, 2036 | Active |
| US11993606 | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof | 17 Oct, 2036 | Active |
| US12077545 | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof | 17 Oct, 2036 | Active |
| US12091415 | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof | 17 Oct, 2036 | Active |
| US12103933 | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof | 17 Oct, 2036 | Active |
| US12110297 | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof | 17 Oct, 2036 | Active |
| US12110298 | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof | 17 Oct, 2036 | Active |
| US12116373 | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof | 17 Oct, 2036 | Active |
| US12134621 | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof | 17 Oct, 2036 | Active |
| US9951080 | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-alpha]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof | 17 Oct, 2036 | Active |
| US9963459 | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-alpla]pyrrolo[2,3-e]-pyrazin-8-YL)-N-(2,2,2-Trifluoroethyl)pyrrol and solid state forms thereof | 17 Oct, 2036 | Active |
| US10537572 | Methods of administering elagolix | 01 Sep, 2036 | Active |
| US10682351 | Methods of administering elagolix | 01 Sep, 2036 | Active |
| US11246866 | Solid pharmaceutical compositions for treating HCV | 24 Jun, 2036 | Active |
| US9321807 | Crystal forms | 05 Dec, 2035 | Active |
| USRE48923 | Crystal forms | 08 Nov, 2035 | Active |
| US10174061 | Carbidopa and L-dopa prodrugs and methods of use | 21 Oct, 2035 | Active |
| US10730895 | Carbidopa prodrug | 21 Oct, 2035 | Active |
| US9446059 | Carbidopa and L-dopa prodrugs and methods of use | 21 Oct, 2035 | Active |
| US9321807 | Crystal forms | 05 Jun, 2035 | Active |
| USRE48923 | Crystal forms | 08 May, 2035 | Active |
| US10117836 | Tablet formulation for CGRP active compounds | 30 Jan, 2035 | Active |
| US11925709 | Tablet formulation for CGRP active compounds | 30 Jan, 2035 | Active |
| US12168004 | Treatment of migraine | 30 Jan, 2035 | Active |
| US12220408 | Treatment of migraine | 30 Jan, 2035 | Active |
| US10105365 | Solid antiviral dosage forms | 02 Jan, 2035 | Active |
| US9333204 | Solid antiviral dosage forms | 02 Jan, 2035 | Active |
| US9744170 | Solid antiviral dosage forms | 02 Jan, 2035 | Active |
| US9492316 | Prostamide-containing intraocular implants and methods of use thereof | 31 Oct, 2034 | Active |
| US9980974 | Prostamide-containing intraocular implants and methods of use thereof | 31 Oct, 2034 | Active |
| US10286029 | Method for treating HCV | 14 Sep, 2034 | Active |
| US11484534 | Methods for treating HCV | 14 Sep, 2034 | Active |
| US9669974 | Protective cap for a dispenser, and discharge device for discharging pharmaceutical and/or cosmetical liquids | 11 May, 2034 | Active |
| US10286029 | Method for treating HCV | 14 Mar, 2034 | Active |
| US11484534 | Methods for treating HCV | 14 Mar, 2034 | Active |
| US10881659 | Methods of treating heavy menstrual bleeding | 14 Mar, 2034 | Active |
| US11045470 | Methods of treating heavy menstrual bleeding | 14 Mar, 2034 | Active |
| US11344551 | Methods of treating heavy menstrual bleeding | 14 Mar, 2034 | Active |
| US11707464 | Methods of treating heavy menstrual bleeding | 14 Mar, 2034 | Active |
| US9676525 | Protective cap for a dispenser, and discharge device for discharging pharmaceutical and/or cosmetical liquids | 07 Feb, 2034 | Active |
| US8912210 | Piperidinone carboxamide azaindane CGRP receptor antagonists | 23 Dec, 2033 | Active |
| US10201542 | Formulations of pyrimidinedione derivative compounds | 18 Oct, 2033 | Active |
| US9629841 | Formulations of pyrimidinedione derivative compounds | 18 Oct, 2033 | Active |
| US10993942 | Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitor | 06 Sep, 2033 | Active |
| US11110087 | Combination therapy of a type II anti-CD20 antibody with a selective Bcl-2 inhibitor | 06 Sep, 2033 | Active |
| US11413282 | Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitor | 06 Sep, 2033 | Active |
| US11590128 | Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitor | 06 Sep, 2033 | Active |
| US9539251 | Combination therapy of a type II anti-CD20 antibody with a selective Bcl-2 inhibitor | 06 Sep, 2033 | Active |
| US9708371 | Treatments for gastrointestinal disorders | 16 Aug, 2033 | Active |
| USRE47221 | Tricyclic compounds | 16 Aug, 2033 | Active |
| US10188632 | Opioid receptor modulator dosage formulations | 14 Mar, 2033 | Active |
| US11007179 | Opioid receptor modulator dosage formulations | 14 Mar, 2033 | Active |
| US11090291 | Opioid receptor modulator dosage formulations | 14 Mar, 2033 | Active |
| US11160792 | Opioid receptor modulator dosage formulations | 14 Mar, 2033 | Active |
| US11229627 | Opioid receptor modulator dosage formulations | 14 Mar, 2033 | Active |
| US11311516 | Opioid receptor modulator dosage formulations | 14 Mar, 2033 | Active |
| US11484527 | Opioid receptor modulator dosage formulations | 14 Mar, 2033 | Active |
| US12097187 | Opioid receptor modulator dosage formulations | 14 Mar, 2033 | Active |
| US9675587 | Opioid receptor modulator dosage formulations | 14 Mar, 2033 | Active |
| US9850246 | Process for making CGRP receptor antagonists | 13 Mar, 2033 | Active |
| US8937150 | Anti-viral compounds | 18 Nov, 2032 | Active |
| US8466159 | Methods for treating HCV | 04 Sep, 2032 | Active |
| US8492386 | Methods for treating HCV | 04 Sep, 2032 | Active |
| US8680106 | Methods for treating HCV | 04 Sep, 2032 | Active |
| US8685984 | Methods for treating HCV | 04 Sep, 2032 | Active |
| US8648037 | Macrocyclic proline derived HCV serine protease inhibitors | 19 Jul, 2032 | Active |
| US8754096 | Piperidinone carboxamide azaindane CGRP receptor antagonists | 19 Jul, 2032 | Active |
| US8969566 | Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof | 15 Jun, 2032 | Active |
| US9284314 | Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof | 15 Jun, 2032 | Active |
| US9695122 | Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof | 15 Jun, 2032 | Active |
| US8865937 | Crystalline forms of (1S,2R)-2-(amino methyl)-N,N-diethyl-1-phenyl cyclopropane carboxamide | 23 May, 2032 | Active |
| US11369599 | Melt-extruded solid dispersions containing an apoptosis-inducing agent | 23 May, 2032 | Active |
| US8937150 | Anti-viral compounds | 18 May, 2032 | Active |
| US10201541 | Compositions and methods for treating HCV | 17 May, 2032 | Active |
| US10201584 | Compositions and methods for treating HCV | 17 May, 2032 | Active |
| US8561859 | Dispensing device | 16 Apr, 2032 | Active |
| US8691938 | Anti-viral compounds | 13 Apr, 2032 | Active |
| US12161653 | Treatment of submental fat | 17 Feb, 2032 | Active |
| US8722657 | Salts and crystalline forms of an apoptosis-inducing agent | 29 Jan, 2032 | Active |
| US8648037 | Macrocyclic proline derived HCV serine protease inhibitors | 19 Jan, 2032 | Active |
| US10730873 | Salts and crystalline forms of an apoptosis-inducing agent | 21 Nov, 2031 | Active |
| US9499545 | Piperidinone carboxamide azaindane CGRP receptor antagonists | 10 Nov, 2031 | Active |
| US9833448 | Piperidinone carboxamide azaindane CGRP receptor antagonists | 10 Nov, 2031 | Active |
| US8748573 | Formulations comprising linaclotide | 30 Oct, 2031 | Active |
| US8802628 | Stable solid formulation of a GC-C receptor agonist polypeptide suitable for oral administration | 30 Oct, 2031 | Active |
| US8420596 | Macrocyclic hepatitis C serine protease inhibitors | 10 Oct, 2031 | Active |
| US8471025 | Crystalline forms of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide sodium salt | 12 Aug, 2031 | Active |
| US10675325 | Stable formulations of linaclotide | 11 Aug, 2031 | Active |
| US10702576 | Stable formulations of linaclotide | 11 Aug, 2031 | Active |
| US8629185 | 7-[3,5-dihydroxy-2- (3-hydroxy-5-phenyl-pent-1-enyl)-cyclopentyl]-N-ethyl-hept-5-enamide (bimatoprost) in crystalline form II, methods for preparation, and methods for use thereof | 15 Jul, 2031 | Active |
| US8546399 | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases | 27 Jun, 2031 | Active |
| US8686026 | Solid compositions | 09 Jun, 2031 | Active |
| US9586978 | Anti-viral compounds | 06 May, 2031 | Active |
| US8420596 | Macrocyclic hepatitis C serine protease inhibitors | 10 Apr, 2031 | Active |
| US9044480 | Compositions and methods for treating HCV | 10 Apr, 2031 | Active |
| US8920392 | Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions | 26 Mar, 2031 | Active |
| US8481598 | Stable dosage forms of levomilnacipran | 02 Mar, 2031 | Active |
| US8292129 | Dispensing device | 25 Feb, 2031 | Active |
| US8933030 | Treatments for gastrointestinal disorders | 17 Feb, 2031 | Active |
| US8247400 | Cephem compounds useful for the treatment of bacterial infections | 10 Feb, 2031 | Active |
| US8962629 | Tricyclic compounds | 15 Jan, 2031 | Active |
| US10028937 | Anti-viral compounds | 10 Dec, 2030 | Active |
| US10039754 | Anti-viral compounds | 10 Dec, 2030 | Active |
| US9586978 | Anti-viral compounds | 06 Nov, 2030 | Active |
| US8835455 | Crystalline forms of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide sodium salt | 08 Oct, 2030 | Active |
| US9629861 | Compositions and methods for treating bacterial infections using ceftaroline | 21 Sep, 2030 | Active |
| US10028937 | Anti-viral compounds | 10 Jun, 2030 | Active |
| US10039754 | Anti-viral compounds | 10 Jun, 2030 | Active |
| US9006387 | Anti-viral compounds | 10 Jun, 2030 | Active |
| US9174982 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | 26 May, 2030 | Active |
| US10500214 | Formulations of deoxycholic acid and salts thereof | 02 Mar, 2030 | Active |
| US8101593 | Formulations of deoxycholic acid and salts thereof | 02 Mar, 2030 | Active |
| US8367649 | Formulations of deoxycholic acid and salts thereof | 02 Mar, 2030 | Active |
| US8653058 | Compositions comprising deoxycholic acid and salts thereof suitable for use in treating fat deposits | 02 Mar, 2030 | Active |
| US9198871 | Delayed release pancreatin compositions | 07 Feb, 2030 | Active |
| US8058291 | Methods and compositions for the treatment of CNS-related conditions | 05 Dec, 2029 | Active |
| US10449173 | Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions | 06 Nov, 2029 | Active |
| US9259388 | Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions | 06 Nov, 2029 | Active |
| US8039009 | Modified release formulations of memantine oral dosage forms | 24 Sep, 2029 | Active |
| US7994220 | Milnacipran for the long-term treatment of fibromyalgia syndrome | 19 Sep, 2029 | Active |
| US7737142 | (Thio) carbamoyl-cyclohexane derivatives as D3/D2 receptor antagonists | 17 Sep, 2029 | Active |
| US8642538 | Macrocyclic hepatitis C serine protease inhibitors | 10 Sep, 2029 | Active |
| US7842714 | Ketorolac tromethamine compositions for treating ocular pain | 15 Aug, 2029 | Active |
| USRE47350 | Pharmaceutical formulations containing dopamine receptor ligands | 16 Jul, 2029 | Active |
| USRE49110 | Pharmaceutical formulations containing dopamine receptor ligands | 16 Jul, 2029 | Active |
| USRE49302 | Pharmaceutical formulations containing dopamine receptor ligands | 16 Jul, 2029 | Active |
| US7419983 | Gonadotropin-releasing hormone receptor antagonists and methods related thereto | 06 Jul, 2029 | Active |
| US7741356 | Compounds as opioid receptor modulators | 27 May, 2029 | Active |
| US8188104 | Anti-infective agents and uses thereof | 17 May, 2029 | Active |
| US7799336 | Hypotensive lipid-containing biodegradable intraocular implants and related methods | 24 Apr, 2029 | Active |
| US8039009 | Modified release formulations of memantine oral dosage forms | 24 Mar, 2029 | Active |
| US7943621 | Salts of piperazine compounds as D3/D2 antagonists | 16 Dec, 2028 | Active |
| US9139536 | Anti-infective agents and uses thereof | 09 Nov, 2028 | Active |
| US11459305 | Processes for the preparation of uracil derivatives | 07 Nov, 2028 | Active |
| US8501238 | Anti-infective agents and uses thereof | 17 Sep, 2028 | Active |
| US8691860 | Crystals and process of making 5-({(2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(-4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid | 07 Jul, 2028 | Active |
| US9115091 | Crystals and process of making 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl—1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid | 07 Jul, 2028 | Active |
| US9364489 | Crystals and process of making 5-({[2-amino-3-(4-Carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid | 07 Jul, 2028 | Active |
| US9789125 | Crystals and process of making 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid | 07 Jul, 2028 | Active |
| US8025899 | Solid pharmaceutical dosage form | 14 Jun, 2028 | Active |
| US8217083 | Mesalamine suppository | 06 Jun, 2028 | Active |
| US8436051 | Mesalamine suppository | 06 Jun, 2028 | Active |
| US6900175 | Methods of administering dalbavancin for treatment of bacterial infections | 23 May, 2028 | Active |
| US8242294 | Synthetic bile acid compositions and methods | 16 May, 2028 | Active |
| US8377952 | Solid pharmaceutical dosage formulation | 22 Apr, 2028 | Active |
| US8512717 | Compositions for delivery of therapeutics into the eyes and methods for making and using same | 07 Mar, 2028 | Active |
| US9192571 | Ketorolac tromethamine compositions for treating or preventing ocular pain | 07 Mar, 2028 | Active |
| US8461140 | Synthetic bile acid compositions and methods | 21 Feb, 2028 | Active |
| US8546367 | Synthetic bile acid compositions and methods | 21 Feb, 2028 | Active |
| US8883770 | Synthetic bile acid compositions and methods | 21 Feb, 2028 | Active |
| US9522155 | Synthetic bile acid compositions and methods | 21 Feb, 2028 | Active |
| US9636349 | Synthetic bile acid compositions and methods | 21 Feb, 2028 | Active |
| US9949986 | Synthetic bile acid compositions and methods | 21 Feb, 2028 | Active |
| US8664215 | Ocular allergy treatments with alcaftadine | 23 Dec, 2027 | Active |
| US8025899 | Solid pharmaceutical dosage form | 14 Dec, 2027 | Active |
| US7622130 | Methods and compositions for the non-surgical removal of fat | 10 Dec, 2027 | Active |
| US7754230 | Methods and related compositions for reduction of fat | 10 Dec, 2027 | Active |
| US8008338 | Ketorolac tromethamine compositions for treating or preventing ocular pain | 24 Nov, 2027 | Active |
| US8377952 | Solid pharmaceutical dosage formulation | 22 Oct, 2027 | Active |
| US7838552 | Compositions comprising nebivolol | 04 Oct, 2027 | Active |
| US7851504 | Enhanced bimatoprost ophthalmic solution | 13 Jun, 2027 | Active |
| US8008338 | Ketorolac tromethamine compositions for treating or preventing ocular pain | 24 May, 2027 | Active |
| US8206737 | Hypotensive lipid-containing biodegradable intraocular implants and related methods | 07 Apr, 2027 | Active |
| US10617695 | Ophthalmic compositions containing alcaftadine | 19 Mar, 2027 | Active |
| US8470347 | Self-emulsifying active substance formulation and use of this formulation | 17 Mar, 2027 | Active |
| US10441543 | Processes for making cyclic lipid implants for intraocular use | 19 Dec, 2026 | Active |
| US9149428 | Processes for making cyclic lipid implants for intraocular use | 19 Dec, 2026 | Active |
| US7612087 | Heterocyclic compounds as inhibitors of beta-lactamases | 12 Nov, 2026 | Active |
| US8470347 | Self-emulsifying active substance formulation and use of this formulation | 17 Sep, 2026 | Active |
| US7304036 | Methods and compositions for the treatment of gastrointestinal disorders | 30 Aug, 2026 | Active |
| US7803838 | Compositions comprising nebivolol | 29 Aug, 2026 | Active |
| US8168209 | Method and composition for administering an NMDA receptor antagonist to a subject | 22 May, 2026 | Active |
| US8173708 | Method and composition for administering an NMDA receptor antagonist to a subject | 22 May, 2026 | Active |
| US8283379 | Methods and compositions for the treatment of CNS-related conditions | 22 May, 2026 | Active |
| US8329752 | Composition for administering an NMDA receptor antagonist to a subject | 22 May, 2026 | Active |
| US8362085 | Method for administering an NMDA receptor antagonist to a subject | 22 May, 2026 | Active |
| US8598233 | Method for administering an NMDA receptor antagonist to a subject | 22 May, 2026 | Active |
| USRE43879 | Use of the dextrogyral enantiomer of milnacipran for the preparation of a drug | 11 Jan, 2026 | Active |
| US7112592 | Azabicyclic compounds, preparation thereof and use as medicines, in particular as antibacterial agents | 07 Jan, 2026 | Active |
| US8168209 | Method and composition for administering an NMDA receptor antagonist to a subject | 22 Nov, 2025 | Active |
| US8173708 | Method and composition for administering an NMDA receptor antagonist to a subject | 22 Nov, 2025 | Active |
| US8283379 | Methods and compositions for the treatment of CNS-related conditions | 22 Nov, 2025 | Active |
| US8329752 | Composition for administering an NMDA receptor antagonist to a subject | 22 Nov, 2025 | Active |
| US8362085 | Method for administering an NMDA receptor antagonist to a subject | 22 Nov, 2025 | Active |
| US8598233 | Method for administering an NMDA receptor antagonist to a subject | 22 Nov, 2025 | Active |
| US8293794 | Methods and compositions for the treatment of CNS-related conditions | 22 Nov, 2025 | Active |
| US8338485 | Compositions for the treatment of CNS-related conditions | 22 Nov, 2025 | Active |
| US8338486 | Methods for the treatment of CNS-related conditions | 22 Nov, 2025 | Active |
| US8580858 | Compositions for the treatment of CNS-related conditions | 22 Nov, 2025 | Active |
| US8298556 | Methods and related compositions for the non-surgical removal of fat | 03 Aug, 2025 | Active |
| US8309613 | Solid pharmaceutical dosage form | 24 Jun, 2025 | Expired |
| US8278353 | Enhanced bimatoprost ophthalmic solution | 16 Mar, 2025 | Expired |
| US8299118 | Enhanced bimatoprost ophthalmic solution | 16 Mar, 2025 | Expired |
| US8309605 | Enhanced bimatoprost ophthalmic solution | 16 Mar, 2025 | Expired |
| US8338479 | Enhanced bimatoprost ophthalmic solution | 16 Mar, 2025 | Expired |
| US8524777 | Enhanced bimatoprost ophthalmic solution | 16 Mar, 2025 | Expired |
| US8586630 | Enhanced bimatoprost ophthalmic solution | 16 Mar, 2025 | Expired |
| US8772338 | Enhanced bimatoprost ophthalmic solution | 16 Mar, 2025 | Expired |
| US8933120 | Enhanced bimatoprost ophthalmic solution | 16 Mar, 2025 | Expired |
| US8933127 | Enhanced bimatoprost ophthalmic solution | 16 Mar, 2025 | Expired |
| US9155716 | Enhanced bimatoprost ophthalmic solution | 16 Mar, 2025 | Expired |
| US9241918 | Enhanced bimatoprost ophthalmic solution | 16 Mar, 2025 | Expired |
| US10213415 | Compounds as opioid receptor modulators | 14 Mar, 2025 | Expired |
| US7786158 | Compounds as opioid receptor modulators | 14 Mar, 2025 | Expired |
| US8344011 | Compounds as opioid receptor modulators | 14 Mar, 2025 | Expired |
| US8609709 | Compounds as opioid receptor modulators | 14 Mar, 2025 | Expired |
| US8772325 | Compounds as opioid receptor modulators | 14 Mar, 2025 | Expired |
| US9205076 | Compounds as opioid receptor modulators | 14 Mar, 2025 | Expired |
| US9700542 | Compounds as opioid receptor modulators | 14 Mar, 2025 | Expired |
| US8268349 | Solid pharmaceutical dosage form | 25 Feb, 2025 | Expired |
| US8399015 | Solid pharmaceutical dosage form | 25 Feb, 2025 | Expired |
| US8691878 | Solid pharmaceutical dosage form | 25 Feb, 2025 | Expired |
| US8673341 | Intraocular pressure reduction with intracameral bimatoprost implants | 19 Feb, 2025 | Expired |
| US8846066 | Methods and related compositions for reduction of fat and skin tightening | 08 Feb, 2025 | Expired |
| US7259186 | Salts of fenofibric acid and pharmaceutical formulations thereof | 07 Jan, 2025 | Expired |
| US8309613 | Solid pharmaceutical dosage form | 24 Dec, 2024 | Expired |
| US8207215 | Ketorolac tromethamine compositions for treating or preventing ocular pain | 28 Nov, 2024 | Expired |
| US8377982 | Ketorolac tromethamine compositions for treating or preventing ocular pain | 28 Nov, 2024 | Expired |
| US8541463 | Ketorolac tromethamine compositions for treating or preventing ocular pain | 28 Nov, 2024 | Expired |
| US7056927 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | 10 Sep, 2024 | Expired |
| US8629111 | Methods of providing therapeutic effects using cyclosporin components | 27 Aug, 2024 | Expired |
| US8633162 | Methods of providing therapeutic effects using cyclosporin components | 27 Aug, 2024 | Expired |
| US8642556 | Methods of providing therapeutic effects using cyclosporin components | 27 Aug, 2024 | Expired |
| US8648048 | Methods of providing therapeutic effects using cyclosporin components | 27 Aug, 2024 | Expired |
| US8685930 | Methods of providing therapeutic effects using cyclosporin components | 27 Aug, 2024 | Expired |
| US9248191 | Methods of providing therapeutic effects using cyclosporin components | 27 Aug, 2024 | Expired |
| US8268349 | Solid pharmaceutical dosage form | 25 Aug, 2024 | Expired |
| US8399015 | Solid pharmaceutical dosage form | 25 Aug, 2024 | Expired |
| US8691878 | Solid pharmaceutical dosage form | 25 Aug, 2024 | Expired |
| US8992952 | Compositions for delivery of therapeutics into the eyes and methods for making and using same | 05 Aug, 2024 | Expired |
| US7176211 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | 06 Jul, 2024 | Expired |
| US8207215 | Ketorolac tromethamine compositions for treating or preventing ocular pain | 28 May, 2024 | Expired |
| US8377982 | Ketorolac tromethamine compositions for treating or preventing ocular pain | 28 May, 2024 | Expired |
| US8541463 | Ketorolac tromethamine compositions for treating or preventing ocular pain | 28 May, 2024 | Expired |
| US8648107 | Ketorolac tromethamine compositions for treating or preventing ocular pain | 28 May, 2024 | Expired |
| US8906950 | Ketorolac tromethamine compositions for treating or preventing ocular pain | 28 May, 2024 | Expired |
| US8946281 | Ketorolac tromethamine compositions for treating or preventing ocular pain | 28 May, 2024 | Expired |
| US9216127 | Burial vault and method for customizing a burial vault | 28 May, 2024 | Expired |
| US9216167 | Ketorolac tromethamine compositions for treating or preventing ocular pain | 28 May, 2024 | Expired |
| US7351404 | Method of enhancing hair growth | 25 May, 2024 | Expired |
| US8101161 | Method of enhancing hair growth | 25 May, 2024 | Expired |
| US10398707 | Hypotensive lipid-containing biodegradable intraocular implants and related implants | 30 Apr, 2024 | Expired |
| US8858961 | Compositions containing alpha-2-adrenergic agonist components | 02 Mar, 2024 | Expired |
| US7371727 | Methods and compositions for the treatment of gastrointestinal disorders | 28 Jan, 2024 | Expired |
| US7704947 | Methods and compositions for the treatment of gastrointestinal disorders | 28 Jan, 2024 | Expired |
| US7745409 | Methods and compositions for the treatment of gastrointestinal disorders | 28 Jan, 2024 | Expired |
| US8080526 | Methods and compositions for the treatment of gastrointestinal disorders | 28 Jan, 2024 | Expired |
| US8110553 | Methods and compositions for the treatment of gastrointestinal disorders | 28 Jan, 2024 | Expired |
| US7115564 | Stable pharmaceutical compositions of dalbavancin and methods of administration | 14 Nov, 2023 | Expired |
| US7119061 | Dalbavancin compositions for treatment of bacterial infections | 14 Nov, 2023 | Expired |
| US8143212 | Dalbavancin compositions for treatment of bacterial infections | 14 Nov, 2023 | Expired |
| US6899717 | Methods and apparatus for delivery of ocular implants | 01 Nov, 2023 | Expired |
| US8858961 | Compositions containing alpha-2-adrenergic agonist components | 02 Sep, 2023 | Expired |
| US8038988 | Method of enhancing hair growth | 25 Aug, 2023 | Expired |
| US8263054 | Method of enhancing hair growth | 25 Aug, 2023 | Expired |
| US7276249 | Nanoparticulate fibrate formulations | 21 Feb, 2023 | Expired |
| US7320802 | Methods of treatment using nanoparticulate fenofibrate compositions | 21 Feb, 2023 | Expired |
| US6916941 | Crystalline composition containing escitalopram | 12 Feb, 2023 | Expired |
| US7420069 | Crystalline composition containing escitalopram | 12 Feb, 2023 | Expired |
| US7323463 | Combination of brimonidine and timolol for topical ophthalmic use | 19 Jan, 2023 | Expired |
| US8632760 | Method of enhancing hair growth | 15 Jan, 2023 | Expired |
| US8758733 | Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists | 15 Jan, 2023 | Expired |
| US8926953 | Method of enhancing hair growth | 15 Jan, 2023 | Expired |
| US8986715 | Method of enhancing hair growth | 15 Jan, 2023 | Expired |
| US9216183 | Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists | 15 Jan, 2023 | Expired |
| US9226931 | Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists | 15 Jan, 2023 | Expired |
| US6602911 | Methods of treating fibromyalgia | 14 Jan, 2023 | Expired |
| US10076526 | Ocular implant made by a double extrusion process | 09 Jan, 2023 | Expired |
| US10702539 | Ocular implant made by a double extrusion process | 09 Jan, 2023 | Expired |
| US8034366 | Ocular implant made by a double extrusion process | 09 Jan, 2023 | Expired |
| US8034370 | Ocular implant made by a double extrusion process | 09 Jan, 2023 | Expired |
| US8506987 | Ocular implant made by a double extrusion process | 09 Jan, 2023 | Expired |
| US9192511 | Ocular implant made by a double extrusion process | 09 Jan, 2023 | Expired |
| US7834020 | Polymorphic forms of 1-′4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride | 05 Dec, 2022 | Expired |
| US8193195 | Polymorphic forms of 1-'4-(5-cyanoindol-3-yl) butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride | 05 Dec, 2022 | Expired |
| US8236804 | Polymorphic forms of 1-′4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride | 05 Dec, 2022 | Expired |
| US8673921 | Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride | 05 Dec, 2022 | Expired |
| US6916941 | Crystalline composition containing escitalopram | 12 Aug, 2022 | Expired |
| US7420069 | Crystalline composition containing escitalopram | 12 Aug, 2022 | Expired |
| US7834020 | Polymorphic forms of 1-′4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride | 05 Jun, 2022 | Expired |
| US8193195 | Polymorphic forms of 1-'4-(5-cyanoindol-3-yl) butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride | 05 Jun, 2022 | Expired |
| US8236804 | Polymorphic forms of 1-′4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride | 05 Jun, 2022 | Expired |
| US8673921 | Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride | 05 Jun, 2022 | Expired |
| US6911214 | Flavoring systems for pharmaceutical compositions and methods of making such compositions | 28 May, 2022 | Expired |
| US7030149 | Combination of brimonidine timolol for topical ophthalmic use | 19 Apr, 2022 | Expired |
| US7320976 | Combination of brimonidine and timolol for topical ophthalmic use | 19 Apr, 2022 | Expired |
| US7642258 | Combination of brimonidine and timolol for topical ophthalmic use | 19 Apr, 2022 | Expired |
| US8133890 | Combination of brimonidine and timolol for topical ophthalmic use | 19 Apr, 2022 | Expired |
| US8354409 | Combination of brimonidine and timolol for topical ophthalmic use | 19 Apr, 2022 | Expired |
| US8748425 | Combination of brimonidine and timolol for topical ophthalmic use | 19 Apr, 2022 | Expired |
| US9474751 | Combination of brimonidine and timolol for topical ophthalmic use | 19 Apr, 2022 | Expired |
| US9770453 | Combination of brimonidine and timolol for topical ophthalmic use | 19 Apr, 2022 | Expired |
| US9907801 | Combination of brimonidine and timolol for topical ophthalmic use | 19 Apr, 2022 | Expired |
| US9907802 | Combination of brimonidine and timolol for topical ophthalmic use | 19 Apr, 2022 | Expired |
| US6641834 | Compositions containing alpha-2-adrenergic agonist components | 28 Jan, 2022 | Expired |
| US6673337 | Compositions containing alpha-2-adrenergic agonist components | 26 Jan, 2022 | Expired |
| US7388029 | Compositions and methods for treating hair loss using non-naturally occurring prostaglandins | 21 Jan, 2022 | Expired |
| US6627210 | Compositions containing α-2-adrenergic agonist components | 18 Jan, 2022 | Expired |
| US6562873 | Compositions containing therapeutically active components having enhanced solubility | 10 Jan, 2022 | Expired |
| US9295641 | Compositions containing alpha-2-adrenergic agonist components | 10 Jan, 2022 | Expired |
| US9687443 | Compositions containing alpha-2-adrenergic agonist components | 10 Jan, 2022 | Expired |
| US6906055 | Phosphonocephem compound | 15 Dec, 2021 | Expired |
| US7419973 | Phosphonocephem compound | 15 Dec, 2021 | Expired |
| US6911214 | Flavoring systems for pharmaceutical compositions and methods of making such compositions | 28 Nov, 2021 | Expired |
| US8501219 | Flavoring systems for pharmaceutical compositions and methods of making such compositions | 28 Nov, 2021 | Expired |
| US7767223 | Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use | 28 Nov, 2021 | Expired |
| US6893662 | Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures | 15 Nov, 2021 | Expired |
| US8580302 | Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures | 15 Nov, 2021 | Expired |
| US9089492 | Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures | 15 Nov, 2021 | Expired |
| US6992110 | Methods of treating fibromyalgia syndrome, chronic fatigue syndrome and pain | 05 Nov, 2021 | Expired |
| US7888342 | Methods of treating fibromyalgia syndrome, chronic fatigue syndrome and pain | 05 Nov, 2021 | Expired |
| US6641834 | Compositions containing alpha-2-adrenergic agonist components | 28 Jul, 2021 | Expired |
| US6673337 | Compositions containing alpha-2-adrenergic agonist components | 26 Jul, 2021 | Expired |
| US8178554 | Heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents | 24 Jul, 2021 | Expired |
| US6627210 | Compositions containing α-2-adrenergic agonist components | 18 Jul, 2021 | Expired |
| US10307368 | Compositions containing alpha-2-adrenergic agonist components | 10 Jul, 2021 | Expired |
| US6562873 | Compositions containing therapeutically active components having enhanced solubility | 10 Jul, 2021 | Expired |
| US9295641 | Compositions containing alpha-2-adrenergic agonist components | 10 Jul, 2021 | Expired |
| US9687443 | Compositions containing alpha-2-adrenergic agonist components | 10 Jul, 2021 | Expired |
| US7364752 | Solid dispersion pharamaceutical formulations | 10 May, 2021 | Expired |
| US7179815 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | 07 Mar, 2021 | Expired |
| US8541466 | Compositions and methods for treating hair loss using non-naturally occurring prostaglandins | 31 Jan, 2021 | Expired |
| US8906962 | Compositions and methods for treating hair loss using non-naturally occurring prostaglandins | 31 Jan, 2021 | Expired |
| US9579270 | Compositions and methods for treating hair loss using non-naturally occurring prostaglandins | 31 Jan, 2021 | Expired |
| US6872728 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | 25 Jan, 2021 | Expired |
| US7462625 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | 25 Jan, 2021 | Expired |
| US7141593 | Pharmaceutical formulations | 22 Nov, 2020 | Expired |
| US7432294 | Pharmaceutical formulations | 22 Nov, 2020 | Expired |
| US7364752 | Solid dispersion pharamaceutical formulations | 10 Nov, 2020 | Expired |
| US7033605 | Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor | 20 Oct, 2020 | Expired |
| US6726918 | Methods for treating inflammation-mediated conditions of the eye | 20 Oct, 2020 | Expired |
| US8043628 | Methods for reducing edema | 20 Oct, 2020 | Expired |
| US8063031 | Implants and methods for treating inflammation-mediated conditions of the eye | 20 Oct, 2020 | Expired |
| US8088407 | Method for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor | 20 Oct, 2020 | Expired |
| US9012437 | Implants and methods for treating inflammation-mediated conditions of the eye | 20 Oct, 2020 | Expired |
| US9283178 | Methods for treating edema in the eye and intraocular implants for use therefor | 20 Oct, 2020 | Expired |
| US9592242 | Methods for treating edema in the eye and intraocular implants for use therefor | 20 Oct, 2020 | Expired |
| US9775849 | Implants and methods for treating inflammation-mediated conditions of the eye | 20 Oct, 2020 | Expired |
| US6375986 | Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate | 21 Sep, 2020 | Expired |
| US7141593 | Pharmaceutical formulations | 22 May, 2020 | Expired |
| US7432294 | Pharmaceutical formulations | 22 May, 2020 | Expired |
| US10272061 | Compositions and methods for unoccluded transdermal oxybutynin therapy | 26 Apr, 2020 | Expired |
| US7029694 | Compositions and methods for transdermal oxybutynin therapy | 26 Apr, 2020 | Expired |
| US7179483 | Compositions and methods for transdermal oxybutynin therapy | 26 Apr, 2020 | Expired |
| US8241662 | Unoccluded topical oxybutynin gel composition and methods for transdermal oxybutynin therapy | 26 Apr, 2020 | Expired |
| US6743441 | Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy | 26 Apr, 2020 | Expired |
| US7081249 | Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy | 26 Apr, 2020 | Expired |
| US7081250 | Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy | 26 Apr, 2020 | Expired |
| US7081251 | Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy | 26 Apr, 2020 | Expired |
| US7081252 | Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy | 26 Apr, 2020 | Expired |
| US6649180 | Hard capsule formed of cellulose ether film with a specific content of methoxyl and hydroxypropoxyl groups | 13 Apr, 2020 | Expired |
| US6333045 | Aqueous liquid pharmaceutical composition comprised of gatifloxacin | 20 Feb, 2020 | Expired |
| US6051567 | Low oxygen content compositions of 1α, 25-dihydroxycholecalciferol | 02 Feb, 2020 | Expired |
| US6265392 | Low oxygen content compositions of 1α, 25-dihydroxycholeclciferol | 02 Feb, 2020 | Expired |
| US6274169 | Low oxygen content compostions of 1α, 25-dihydroxycholecalciferol | 02 Feb, 2020 | Expired |
| US7148359 | Polymorph of a pharmaceutical | 19 Jan, 2020 | Expired |
| US6333045 | Aqueous liquid pharmaceutical composition comprised of gatifloxacin | 20 Aug, 2019 | Expired |
| US6051567 | Low oxygen content compositions of 1α, 25-dihydroxycholecalciferol | 02 Aug, 2019 | Expired |
| US6265392 | Low oxygen content compositions of 1α, 25-dihydroxycholeclciferol | 02 Aug, 2019 | Expired |
| US6274169 | Low oxygen content compostions of 1α, 25-dihydroxycholecalciferol | 02 Aug, 2019 | Expired |
| US7148359 | Polymorph of a pharmaceutical | 19 Jul, 2019 | Expired |
| US6419953 | Controlled release formulation of divalproex sodium | 18 Jun, 2019 | Expired |
| US6511678 | Controlled release formulation of divalproex sodium | 18 Jun, 2019 | Expired |
| US6528090 | Controlled release formulation of divalproex sodium | 18 Jun, 2019 | Expired |
| US6528091 | Controlled release formulation of divalproex sodium | 18 Jun, 2019 | Expired |
| US6713086 | Controlled release formulation of divalproex sodium | 18 Jun, 2019 | Expired |
| US6720004 | Controlled release formulation of divalproex sodium | 18 Jun, 2019 | Expired |
| US6419953 | Controlled release formulation of divalproex sodium | 18 Dec, 2018 | Expired |
| US6511678 | Controlled release formulation of divalproex sodium | 18 Dec, 2018 | Expired |
| US6528090 | Controlled release formulation of divalproex sodium | 18 Dec, 2018 | Expired |
| US6528091 | Controlled release formulation of divalproex sodium | 18 Dec, 2018 | Expired |
| US6713086 | Controlled release formulation of divalproex sodium | 18 Dec, 2018 | Expired |
| US6720004 | Controlled release formulation of divalproex sodium | 18 Dec, 2018 | Expired |
| US6417175 | Phosphonocephem derivatives, process for the preparation of the same, and use thereof | 17 Dec, 2018 | Expired |
| US5387603 | 1,5,7-trisubstituted indoline compounds and salts thereof | 01 Dec, 2018 | Expired |
| US6136799 | Cosolvent formulations | 08 Oct, 2018 | Expired |
| US6361758 | Cosolvent formulations | 08 Oct, 2018 | Expired |
| US6074668 | Container for an inhalation anesthetic | 09 Jul, 2018 | Expired |
| US6232333 | Pharmaceutical composition | 07 May, 2018 | Expired |
| US6458818 | Pharmaceutical composition | 07 May, 2018 | Expired |
| US6521651 | Pharmaceutical composition | 07 May, 2018 | Expired |
| US6136799 | Cosolvent formulations | 08 Apr, 2018 | Expired |
| US6361758 | Cosolvent formulations | 08 Apr, 2018 | Expired |
| US6469035 | Methods of pretreating hyperlipidemic individuals with a flush inhibiting agent prior to the start of single daily dose nicotinic acid therapy to reduce flushing provoked by nicotinic acid | 15 Mar, 2018 | Expired |
| US6074670 | Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it | 09 Jan, 2018 | Expired |
| US6277405 | Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it | 09 Jan, 2018 | Expired |
| US6589552 | Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it | 09 Jan, 2018 | Expired |
| US6652881 | Fenofibrate pharmaceutical composition having high bioavailability | 09 Jan, 2018 | Expired |
| US7037529 | Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it | 09 Jan, 2018 | Expired |
| US7041319 | Fenofibrate pharmaceutical composition having high bioavailabilty | 09 Jan, 2018 | Expired |
| US6074668 | Container for an inhalation anesthetic | 09 Jan, 2018 | Expired |
| US6232333 | Pharmaceutical composition | 07 Nov, 2017 | Expired |
| US6458818 | Pharmaceutical composition | 07 Nov, 2017 | Expired |
| US6521651 | Pharmaceutical composition | 07 Nov, 2017 | Expired |
| US5990176 | Fluoroether compositions and methods for inhibiting their degradation in the presence of a Lewis acid | 27 Jul, 2017 | Expired |
| US6288127 | Fluoroether compositions and methods for inhibiting their degradation in the presence of a Lewis acid | 27 Jul, 2017 | Expired |
| US6444859 | Fluoroether compositions and methods for inhibiting their degradation in the presence of a Lewis acid | 27 Jul, 2017 | Expired |
| US6551616 | Extended release formulations of erythromycin derivatives | 15 Jul, 2017 | Expired |
| US6348216 | Ibuprofen and narcotic analgesic compositions | 10 Jun, 2017 | Expired |
| US6599531 | Method of making ibuprofen and narcotic analgesic compositions | 10 Jun, 2017 | Expired |
| US6080428 | Nicotinic acid compositions for treating hyperlipidemia and related methods therefor | 27 May, 2017 | Expired |
| US6010718 | Extended release formulations of erythromycin derivatives | 11 Apr, 2017 | Expired |
| US5990176 | Fluoroether compositions and methods for inhibiting their degradation in the presence of a Lewis acid | 27 Jan, 2017 | Expired |
| US6288127 | Fluoroether compositions and methods for inhibiting their degradation in the presence of a Lewis acid | 27 Jan, 2017 | Expired |
| US6444859 | Fluoroether compositions and methods for inhibiting their degradation in the presence of a Lewis acid | 27 Jan, 2017 | Expired |
| US6037157 | Method for improving pharmacokinetics | 26 Dec, 2016 | Expired |
| US6703403 | Method for improving pharmacokinetics | 26 Dec, 2016 | Expired |
| US5863560 | Compositions and methods for topical application of therapeutic agents | 11 Sep, 2016 | Expired |
| US6060085 | Compositions and methods for topical application of therapeutic agents | 11 Sep, 2016 | Expired |
| US6620435 | Compositions for topical application of therapeutic agents | 11 Sep, 2016 | Expired |
| US6106864 | Pharmaceutical formulations containing darifenacin | 21 Aug, 2016 | Expired |
| US6284767 | Retroviral protease inhibiting compounds | 15 Aug, 2016 | Expired |
| US6037157 | Method for improving pharmacokinetics | 26 Jun, 2016 | Expired |
| US6703403 | Method for improving pharmacokinetics | 26 Jun, 2016 | Expired |
| US5914332 | Retroviral protease inhibiting compounds | 13 Jun, 2016 | Expired |
| US5880283 | 8-alkoxyquinolonecarboxylic acid hydrate with excellent stability and process for producing the same | 05 Jun, 2016 | Expired |
| US6284767 | Retroviral protease inhibiting compounds | 15 Feb, 2016 | Expired |
| US5597815 | Prevention of hyperphosphatemia in kidney disorder patients | 13 Jan, 2016 | Expired |
| US5914332 | Retroviral protease inhibiting compounds | 13 Dec, 2015 | Expired |
| US5880283 | 8-alkoxyquinolonecarboxylic acid hydrate with excellent stability and process for producing the same | 05 Dec, 2015 | Expired |
| US5061703 | Adamantane derivatives in the prevention and treatment of cerebral ischemia | 11 Oct, 2015 | Expired |
| US5597815 | Prevention of hyperphosphatemia in kidney disorder patients | 13 Jul, 2015 | Expired |
| US5744496 | Method of treating cardiac insufficiency using angiotensin-converting enzyme inhibitors | 28 Apr, 2015 | Expired |
| US5601839 | Triacetin as a penetration enhancer for transdermal delivery of a basic drug | 26 Apr, 2015 | Expired |
| US5834010 | Triacetin as a penetration enhancer for transdermal delivery of a basic drug | 26 Apr, 2015 | Expired |
| US5061703 | Adamantane derivatives in the prevention and treatment of cerebral ischemia | 11 Apr, 2015 | Expired |
| US5096890 | Pyrrolidine derivatives | 13 Mar, 2015 | Expired |
| US5721244 | Combination of angiotensin-converting enzyme inhibitors with calcium antagonists as well as their use in drugs | 24 Feb, 2015 | Expired |
| US5648497 | Retroviral protease inhibiting compounds | 15 Jan, 2015 | Expired |
| US5532241 | Piperidines and piperazines | 29 Sep, 2014 | Expired |
| US5688819 | Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents | 19 Aug, 2014 | Expired |
| US5656650 | Angiotensin II receptor blocking compositions | 12 Aug, 2014 | Expired |
| US5484801 | Pharmaceutical composition for inhibiting HIV protease | 28 Jul, 2014 | Expired |
| US5648497 | Retroviral protease inhibiting compounds | 15 Jul, 2014 | Expired |
| US5648394 | Topical composition for inhibiting hair growth | 15 Jul, 2014 | Expired |
| US5587497 | 19-nor-vitamin D compounds | 24 Jun, 2014 | Expired |
| US7189761 | Nitric oxide donor composition and method for treatment of anal disorders | 27 May, 2014 | Expired |
| US5886036 | Retroviral protease inhibiting compounds | 19 May, 2014 | Expired |
| US5474979 | Nonirritating emulsions for sensitive tissue | 17 May, 2014 | Expired |
| US5948436 | Pharmaceutical composition | 13 Mar, 2014 | Expired |
| US5541206 | Retroviral protease inhibiting compounds | 30 Jan, 2014 | Expired |
| US5635523 | Retroviral protease inhibiting compounds | 30 Jan, 2014 | Expired |
| US5674882 | Retroviral protease inhibiting compounds | 30 Jan, 2014 | Expired |
| US5484801 | Pharmaceutical composition for inhibiting HIV protease | 28 Jan, 2014 | Expired |
| US5587497 | 19-nor-vitamin D compounds | 24 Dec, 2013 | Expired |
| US5468743 | Imidazo[2,1-b]benzazepine derivatives, compositions and method of use | 21 Nov, 2013 | Expired |
| US5886036 | Retroviral protease inhibiting compounds | 19 Nov, 2013 | Expired |
| US6129930 | Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night | 20 Sep, 2013 | Expired |
| US6406715 | Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique urinary metabolite profiles | 20 Sep, 2013 | Expired |
| US6676967 | Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia | 20 Sep, 2013 | Expired |
| US6746691 | Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics | 20 Sep, 2013 | Expired |
| US6818229 | Intermediate release nicotinic acid compositions for treating hyperlipidemia | 20 Sep, 2013 | Expired |
| US7011848 | Hydrophobic component free sustained release nicotinic acid compositions for treating hyperlipidemia and related methods therefor | 20 Sep, 2013 | Expired |
| US7998506 | Nicotinic acid compositions for treating hyperlipidemia and related methods therefor | 20 Sep, 2013 | Expired |
| US5543150 | Method of progesterone delivery and affect thereof | 15 Sep, 2013 | Expired |
| US5948436 | Pharmaceutical composition | 13 Sep, 2013 | Expired |
| US5541170 | Orally administrable pharmaceutical compositions | 30 Jul, 2013 | Expired |
| US5541171 | Orally administrable pharmaceutical composition | 30 Jul, 2013 | Expired |
| US5541206 | Retroviral protease inhibiting compounds | 30 Jul, 2013 | Expired |
| US5635523 | Retroviral protease inhibiting compounds | 30 Jul, 2013 | Expired |
| US5674882 | Retroviral protease inhibiting compounds | 30 Jul, 2013 | Expired |
| US5424078 | Aqueous ophthalmic formulations and methods for preserving same | 13 Dec, 2012 | Expired |
| US8017655 | Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents | 27 Nov, 2012 | Expired |
| US5403847 | Use of α1C specific compounds to treat benign prostatic hyperlasia | 13 Nov, 2012 | Expired |
| US5780485 | Use of α1c specific compounds to treat benign prostatic hyperplasia | 13 Nov, 2012 | Expired |
| US6015819 | Use of alpha-1C specific compounds to treat benign prostatic hyperplasia | 13 Nov, 2012 | Expired |
| US5246925 | 19-nor-vitamin D compounds for use in treating hyperparathyroidism | 17 Oct, 2012 | Expired |
| US5453510 | Neuromuscular blocking agents | 26 Sep, 2012 | Expired |
| US6403649 | Non-acidic cyclopentane heptanoic acid,2-cycloalkyl or arylalkyl derivatives as therapeutic agents | 21 Sep, 2012 | Expired |
Latest Legal Activities on Abbvie's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Abbvie.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Mail O.P. Petition Decision | 19 Jul, 2024 | US11369599 |
|
Email Notification
Critical
| 19 Jul, 2024 | US11369599 |
| Mail-Petition Decision - Granted | 16 Jul, 2024 | US11369599 |
| Mail-Petition Decision - Denied | 16 Jul, 2024 | US11369599 |
| O.P. Petition Decision | 15 Jul, 2024 | US11369599 |
| Petition Decision - Denied | 15 Jul, 2024 | US11369599 |
|
Petition Decision - Granted
Critical
| 15 Jul, 2024 | US11369599 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 11 Jul, 2024 | US8367649 |
| Post Issue Communication - Certificate of Correction | 08 Jul, 2024 | US11542239 |
| Post Issue Communication - Certificate of Correction | 08 Jul, 2024 | US11542239 |
|
Expire Patent
Critical
| 08 Jul, 2024 | US8193195 (Litigated) |
| Mail Certificate of Correction Memo | 05 Jul, 2024 | US11542239 |
| Mail Certificate of Correction Memo | 05 Jul, 2024 | US11542239 |
| Certificate of Correction Memo | 02 Jul, 2024 | US11542239 |
| Certificate of Correction Memo | 02 Jul, 2024 | US11542239 |
Abbvie's Drug Patent Litigations
Abbvie's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Aug 02, 2006, against patent number US8008338. The petitioner , challenged the validity of this patent, with Christopher A. Muller et al as the respondent. Click below to track the latest information on how companies are challenging Abbvie's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US11110087 | October, 2022 |
Final Written Decision - Appealed
(16 Apr, 2024)
| Genentech, Inc. et al. | Dr. Reddy's Laboratories, Inc. et al. |
| US10993942 | February, 2022 |
Final Written Decision - Appealed
(10 Aug, 2023)
| Genentech, Inc. et al. | Dr. Reddy's Laboratories, Inc. et al. |
| US8648048 | January, 2017 |
Terminated
(27 Sep, 2019)
| Allergan, Inc. | Teva Pharmaceuticals USA, Inc. |
| US9248191 | June, 2016 |
Terminated
(27 Sep, 2019)
| Allergan, Inc. | Mylan Pharmaceuticals Inc. et al. |
| US8642556 | June, 2016 |
FWD Entered
(27 Sep, 2019)
| Allergan, Inc. | Mylan Pharmaceuticals Inc. |
| US8685930 | June, 2016 |
Terminated
(27 Sep, 2019)
| Allergan, Inc. | Mylan Pharmaceuticals Inc. et al. |
| US8629111 | June, 2016 |
Terminated
(27 Sep, 2019)
| Allergan, Inc. | Mylan Pharmaceuticals Inc. et al. |
| US8633162 | June, 2016 |
FWD Entered
(27 Sep, 2019)
| Allergan, Inc. | Mylan Pharmaceuticals Inc. |
| US8629111 | January, 2017 |
Terminated
(27 Sep, 2019)
| Allergan, Inc. | Akorn, Inc. |
| US8648048 | June, 2016 |
Terminated
(27 Sep, 2019)
| Allergan, Inc. | Mylan Pharmaceuticals Inc. et al. |
| US8685930 | January, 2017 |
Terminated
(27 Sep, 2019)
| Allergan, Inc. | Akorn, Inc. |
| US9248191 | January, 2017 |
Terminated
(27 Sep, 2019)
| Allergan, Inc. | Teva Pharmaceuticals USA, Inc. |
| US8633162 | January, 2017 |
FWD Entered
(27 Sep, 2019)
| Allergan, Inc. | Teva Pharmaceuticals USA, Inc. |
| US8642556 | January, 2017 |
FWD Entered
(27 Sep, 2019)
| Allergan, Inc. | Akorn, Inc. |
| US8673921 | January, 2018 |
Terminated-Denied
(23 Jul, 2018)
| Merck Patentgesellschaft Mit Beschrankter Haftung | Argentum Pharmaceuticals LLC |
| US6649180 | November, 2016 |
Terminated-Settled
(19 Dec, 2017)
| Qualicaps Co., Ltd. | Mylan Pharmaceuticals Inc. |
| US8642556 | January, 2017 |
Terminated-Settled
(06 Sep, 2017)
| Allergan, Inc. | Famy Care Limited |
| US8629111 | January, 2017 |
Terminated-Settled
(06 Sep, 2017)
| Allergan, Inc. | Famy Care Limited |
| US8648048 | January, 2017 |
Terminated-Settled
(06 Sep, 2017)
| Allergan, Inc. | Famy Care Limited |
| US8633162 | January, 2017 |
Terminated-Settled
(06 Sep, 2017)
| Allergan, Inc. | Famy Care Limited |
| US8685930 | January, 2017 |
Terminated-Settled
(06 Sep, 2017)
| Allergan, Inc. | Famy Care Limited |
| US9248191 | January, 2017 |
Terminated-Settled
(06 Sep, 2017)
| Allergan, Inc. | Famy Care Limited |
| US8629111 | January, 2017 |
Terminated
(31 Mar, 2017)
| Allergan, Inc. | Teva Pharmaceuticals USA, Inc. |
| US9248191 | January, 2017 |
Terminated
(31 Mar, 2017)
| Allergan, Inc. | Akorn, Inc. |
| US8648048 | January, 2017 |
Terminated
(31 Mar, 2017)
| Allergan, Inc. | Akorn, Inc. |
| US8642556 | January, 2017 |
FWD Entered
(31 Mar, 2017)
| Allergan, Inc. | Teva Pharmaceuticals USA, Inc. |
| US8685930 | January, 2017 |
Terminated
(31 Mar, 2017)
| Allergan, Inc. | Teva Pharmaceuticals USA, Inc. |
| US8633162 | January, 2017 |
FWD Entered
(31 Mar, 2017)
| Allergan, Inc. | Akorn, Inc. |
| US8629111 | June, 2016 |
Terminated-Settled
(08 Dec, 2016)
| Allergan, Inc. | Argentum Pharmaceuticals LLC |
| US8648048 | June, 2015 |
Terminated-Denied
(16 Dec, 2015)
| Allergan, Inc. | Apotex Corp. |
| US8685930 | June, 2015 |
Terminated-Denied
(16 Dec, 2015)
| Allergan, Inc. | Apotex Corp. |
| US8642556 | June, 2015 |
Terminated-Denied
(16 Dec, 2015)
| Allergan, Inc. | Apotex Corp. |
| US8633162 | June, 2015 |
Terminated-Denied
(16 Dec, 2015)
| Allergan, Inc. | Apotex Corp. |
| US8629111 | June, 2015 |
Terminated-Denied
(16 Dec, 2015)
| Allergan, Inc. | Apotex Corp. |
| US7030149 | March, 2015 |
Terminated-Denied
(21 Sep, 2015)
| Allergan Sales, LLC | Ferrum Ferro Capital, LLC |
| US8362085 | December, 2014 |
Terminated-Denied
(15 May, 2015)
| Adamas Pharmaceuticals, Inc. | Ranbaxy, Inc. |
| US8008338 | November, 2010 |
Decision
(29 Mar, 2011)
| Christopher A. Muller et al | |
| US8470347 | August, 2009 |
Decision
(27 May, 2010)
| Gunther Berndl et al | |
| US7851504 | January, 2009 |
Decision
(10 May, 2010)
| Chin-Ming Chang et al | |
| US8008338 | August, 2006 |
Decision
(21 Dec, 2006)
| Christopher A. Muller et al | |
Abbvie Drug Patents' Oppositions Filed in EPO
Abbvie drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Oct 11, 2005, by Egis Gyogyszergyar Rt.. This opposition was filed on patent number EP02750846A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
| | |||
| EP19729883A | Dec, 2022 | Teva Pharmaceutical Industries Ltd. | Granted and Under Opposition |
| EP17165207A | May, 2021 | Generics (U.K.) Limited | Granted and Under Opposition |
| EP17182561A | Nov, 2019 | Lederer & Keller Patentanwälte Partnerschaft mbB | Patent maintained as amended |
| EP03789744A | Jul, 2019 | Fresenius Kabi Deutschland GmbH | Granted and Under Opposition |
| EP14774006A | May, 2019 | Sandoz AG | Opposition rejected |
| EP15176068A | Apr, 2019 | Aechter, Bernd | Revoked |
| EP14815668A | Oct, 2018 | Epping Hermann Fischer Patentanwaltgesellschaft MBH | Patent maintained as amended |
| EP11791401A | May, 2018 | Generics (U.K.) Limited | Revoked |
| EP10835061A | Feb, 2018 | Generics (U.K.) Limited | Opposition rejected |
| EP14719977A | Jan, 2018 | Generics (U.K.) Limited | Granted and Under Opposition |
| EP12753313A | Sep, 2017 | Hexal AG | Revoked |
| EP11727080A | Apr, 2016 | KELTIE LLP | Patent maintained as amended |
| EP11727080A | Apr, 2016 | Ter Meer Steinmeister & Partner Patentanwälte mbB | Patent maintained as amended |
| EP05852057A | Dec, 2013 | Elend, Almut Susanne | Revoked |
| EP10185774A | Dec, 2013 | Generics [UK] Limited | Revoked |
| EP07017089A | Dec, 2013 | Generics [UK] Limited | Revoked |
| EP03726234A | Oct, 2013 | Hexal AG | Revoked |
| EP03726234A | Oct, 2013 | Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi | Revoked |
| EP03726234A | Oct, 2013 | Generics [UK] Limited | Revoked |
| EP03726234A | Oct, 2013 | Alfred E. Tiefenbacher GmbH & Co. KG | Revoked |
| EP03726234A | Oct, 2013 | Teva Pharmaceutical Industries LTD. | Revoked |
| EP03726234A | Oct, 2013 | STADA Arzneimittel AG | Revoked |
| EP10170038A | Mar, 2013 | Generics [UK] Limited | Opposition rejected |
| EP06749777A | Jun, 2011 | Merz Pharma GmbH & Co. KGaA | Revoked |
| EP04780382A | Jul, 2010 | ALCON LABORATORIES, INC. | Patent maintained as amended |
| EP06738208A | Feb, 2010 | Teva Pharmaceutical Industries Ltd. | Patent maintained as amended |
| EP06738208A | Feb, 2010 | Ratiopharm GmbH | Patent maintained as amended |
| EP04029282A | Oct, 2007 | Ratiopharm GmbH | Revoked |
| EP04029282A | Oct, 2007 | Krka, Tovarna Zdravil, d.d. | Revoked |
| EP04029282A | Oct, 2007 | Generics [UK] Limited | Revoked |
| EP04029282A | Oct, 2007 | Actavis Group hf | Revoked |
| EP04029282A | Oct, 2007 | EGIS Gyógyszergyár Nyrt | Revoked |
| EP04029282A | Sep, 2007 | Pliva Hrvatska D.O.O. | Revoked |
| EP03723781A | Jul, 2007 | Abraxis BioScience, Inc. | Patent maintained as amended |
| EP03723781A | Jul, 2007 | Baxter Healthcare Corporation | Patent maintained as amended |
| EP04029282A | Jan, 2007 | SANDOZ AG | Revoked |
| EP02750846A | Oct, 2005 | Egis Gyogyszergyar RT. | Revoked |
Abbvie's Family Patents
Abbvie drugs have patent protection in a total of 74 countries. It's US patent count contributes only to 27.3% of its total global patent coverage. 15 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click
below to unlock the full patent family tree.
Abbvie Drug List
Given below is the complete list of Abbvie's drugs and the patents protecting them.
1. Acular Ls
Acular Ls is protected by 13 patents, out of which 11 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8008338
(Pediatric)
| Ketorolac tromethamine compositions for treating or preventing ocular pain |
24 Nov, 2027
(2 years from now)
| Active |
| US8008338 | Ketorolac tromethamine compositions for treating or preventing ocular pain |
24 May, 2027
(1 year, 10 months from now)
| Active |
| US8207215
(Pediatric)
| Ketorolac tromethamine compositions for treating or preventing ocular pain |
28 Nov, 2024
(7 months ago)
| Expired |
| US8377982
(Pediatric)
| Ketorolac tromethamine compositions for treating or preventing ocular pain |
28 Nov, 2024
(7 months ago)
| Expired |
| US8541463
(Pediatric)
| Ketorolac tromethamine compositions for treating or preventing ocular pain |
28 Nov, 2024
(7 months ago)
| Expired |
| US8207215 | Ketorolac tromethamine compositions for treating or preventing ocular pain |
28 May, 2024
(1 year, 1 month ago)
| Expired |
| US8377982 | Ketorolac tromethamine compositions for treating or preventing ocular pain |
28 May, 2024
(1 year, 1 month ago)
| Expired |
| US8541463 | Ketorolac tromethamine compositions for treating or preventing ocular pain |
28 May, 2024
(1 year, 1 month ago)
| Expired |
| US8648107 | Ketorolac tromethamine compositions for treating or preventing ocular pain |
28 May, 2024
(1 year, 1 month ago)
| Expired |
| US8906950 | Ketorolac tromethamine compositions for treating or preventing ocular pain |
28 May, 2024
(1 year, 1 month ago)
| Expired |
| US8946281 | Ketorolac tromethamine compositions for treating or preventing ocular pain |
28 May, 2024
(1 year, 1 month ago)
| Expired |
| US9216127 | Burial vault and method for customizing a burial vault |
28 May, 2024
(1 year, 1 month ago)
| Expired |
| US9216167 | Ketorolac tromethamine compositions for treating or preventing ocular pain |
28 May, 2024
(1 year, 1 month ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Acular Ls's drug page
2. Acuvail
Acuvail is protected by 4 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7842714 | Ketorolac tromethamine compositions for treating ocular pain |
15 Aug, 2029
(4 years from now)
| Active |
| US8512717 | Compositions for delivery of therapeutics into the eyes and methods for making and using same |
07 Mar, 2028
(2 years from now)
| Active |
| US9192571 | Ketorolac tromethamine compositions for treating or preventing ocular pain |
07 Mar, 2028
(2 years from now)
| Active |
| US8992952 | Compositions for delivery of therapeutics into the eyes and methods for making and using same |
05 Aug, 2024
(10 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Acuvail's drug page
3. Aczone
Aczone is protected by 3 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5863560 | Compositions and methods for topical application of therapeutic agents |
11 Sep, 2016
(8 years ago)
| Expired |
| US6060085 | Compositions and methods for topical application of therapeutic agents |
11 Sep, 2016
(8 years ago)
| Expired |
| US6620435 | Compositions for topical application of therapeutic agents |
11 Sep, 2016
(8 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Aczone's drug page
4. Advicor
Advicor is protected by 9 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6469035 | Methods of pretreating hyperlipidemic individuals with a flush inhibiting agent prior to the start of single daily dose nicotinic acid therapy to reduce flushing provoked by nicotinic acid |
15 Mar, 2018
(7 years ago)
| Expired |
| US6080428 | Nicotinic acid compositions for treating hyperlipidemia and related methods therefor |
27 May, 2017
(8 years ago)
| Expired |
| US6129930 | Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night |
20 Sep, 2013
(11 years ago)
| Expired |
| US6406715 | Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique urinary metabolite profiles |
20 Sep, 2013
(11 years ago)
| Expired |
| US6676967 | Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia |
20 Sep, 2013
(11 years ago)
| Expired |
| US6746691 | Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics |
20 Sep, 2013
(11 years ago)
| Expired |
| US6818229 | Intermediate release nicotinic acid compositions for treating hyperlipidemia |
20 Sep, 2013
(11 years ago)
| Expired |
| US7011848 | Hydrophobic component free sustained release nicotinic acid compositions for treating hyperlipidemia and related methods therefor |
20 Sep, 2013
(11 years ago)
| Expired |
| US7998506 | Nicotinic acid compositions for treating hyperlipidemia and related methods therefor |
20 Sep, 2013
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Advicor's drug page
5. Alphagan P
Alphagan P is protected by 16 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8858961
(Pediatric)
| Compositions containing alpha-2-adrenergic agonist components |
02 Mar, 2024
(1 year, 4 months ago)
| Expired |
| US8858961 | Compositions containing alpha-2-adrenergic agonist components |
02 Sep, 2023
(1 year, 9 months ago)
| Expired |
| US6641834
(Pediatric)
| Compositions containing alpha-2-adrenergic agonist components |
28 Jan, 2022
(3 years ago)
| Expired |
| US6673337
(Pediatric)
| Compositions containing alpha-2-adrenergic agonist components |
26 Jan, 2022
(3 years ago)
| Expired |
| US6627210
(Pediatric)
| Compositions containing α-2-adrenergic agonist components |
18 Jan, 2022
(3 years ago)
| Expired |
| US6562873
(Pediatric)
| Compositions containing therapeutically active components having enhanced solubility |
10 Jan, 2022
(3 years ago)
| Expired |
| US9295641
(Pediatric)
| Compositions containing alpha-2-adrenergic agonist components |
10 Jan, 2022
(3 years ago)
| Expired |
| US9687443
(Pediatric)
| Compositions containing alpha-2-adrenergic agonist components |
10 Jan, 2022
(3 years ago)
| Expired |
| US6641834 | Compositions containing alpha-2-adrenergic agonist components |
28 Jul, 2021
(3 years ago)
| Expired |
| US6673337 | Compositions containing alpha-2-adrenergic agonist components |
26 Jul, 2021
(3 years ago)
| Expired |
| US6627210 | Compositions containing α-2-adrenergic agonist components |
18 Jul, 2021
(3 years ago)
| Expired |
| US10307368 | Compositions containing alpha-2-adrenergic agonist components |
10 Jul, 2021
(3 years ago)
| Expired |
| US6562873 | Compositions containing therapeutically active components having enhanced solubility |
10 Jul, 2021
(3 years ago)
| Expired |
| US9295641 | Compositions containing alpha-2-adrenergic agonist components |
10 Jul, 2021
(3 years ago)
| Expired |
| US9687443 | Compositions containing alpha-2-adrenergic agonist components |
10 Jul, 2021
(3 years ago)
| Expired |
| US5424078
(Pediatric)
| Aqueous ophthalmic formulations and methods for preserving same |
13 Dec, 2012
(12 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Alphagan P's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List
6. Asacol Hd
Asacol Hd is protected by 5 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6893662 | Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures |
15 Nov, 2021
(3 years ago)
| Expired |
| US8580302 | Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures |
15 Nov, 2021
(3 years ago)
| Expired |
| US9089492 | Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures |
15 Nov, 2021
(3 years ago)
| Expired |
| US5541170 | Orally administrable pharmaceutical compositions |
30 Jul, 2013
(11 years ago)
| Expired |
| US5541171 | Orally administrable pharmaceutical composition |
30 Jul, 2013
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Asacol Hd's drug page
7. Avycaz
Avycaz is protected by 8 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8969566 | Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof |
15 Jun, 2032
(6 years from now)
| Active |
| US9284314 | Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof |
15 Jun, 2032
(6 years from now)
| Active |
| US9695122 | Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof |
15 Jun, 2032
(6 years from now)
| Active |
| US8471025 | Crystalline forms of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide sodium salt |
12 Aug, 2031
(6 years from now)
| Active |
| US8835455 | Crystalline forms of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide sodium salt |
08 Oct, 2030
(5 years from now)
| Active |
| US7612087 | Heterocyclic compounds as inhibitors of beta-lactamases |
12 Nov, 2026
(1 year, 4 months from now)
| Active |
| US7112592 | Azabicyclic compounds, preparation thereof and use as medicines, in particular as antibacterial agents |
07 Jan, 2026
(6 months from now)
| Active |
| US8178554 | Heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents |
24 Jul, 2021
(3 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Avycaz's drug page
8. Biaxin Xl
Biaxin Xl is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6551616 | Extended release formulations of erythromycin derivatives |
15 Jul, 2017
(7 years ago)
| Expired |
| US6010718 | Extended release formulations of erythromycin derivatives |
11 Apr, 2017
(8 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Biaxin Xl's drug page
9. Byvalson
Byvalson is protected by 2 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7838552 | Compositions comprising nebivolol |
04 Oct, 2027
(2 years from now)
| Active |
| US7803838 | Compositions comprising nebivolol |
29 Aug, 2026
(1 year, 1 month from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Byvalson's drug page
10. Calcijex
Calcijex is protected by 6 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6051567
(Pediatric)
| Low oxygen content compositions of 1α, 25-dihydroxycholecalciferol |
02 Feb, 2020
(5 years ago)
| Expired |
| US6265392
(Pediatric)
| Low oxygen content compositions of 1α, 25-dihydroxycholeclciferol |
02 Feb, 2020
(5 years ago)
| Expired |
| US6274169
(Pediatric)
| Low oxygen content compostions of 1α, 25-dihydroxycholecalciferol |
02 Feb, 2020
(5 years ago)
| Expired |
| US6051567 | Low oxygen content compositions of 1α, 25-dihydroxycholecalciferol |
02 Aug, 2019
(5 years ago)
| Expired |
| US6265392 | Low oxygen content compositions of 1α, 25-dihydroxycholeclciferol |
02 Aug, 2019
(5 years ago)
| Expired |
| US6274169 | Low oxygen content compostions of 1α, 25-dihydroxycholecalciferol |
02 Aug, 2019
(5 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Calcijex's drug page
11. Canasa
Canasa is protected by 2 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8217083 | Mesalamine suppository |
06 Jun, 2028
(2 years from now)
| Active |
| US8436051 | Mesalamine suppository |
06 Jun, 2028
(2 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Canasa's drug page
12. Combigan
Combigan is protected by 11 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7323463 | Combination of brimonidine and timolol for topical ophthalmic use |
19 Jan, 2023
(2 years ago)
| Expired |
| US7030149 | Combination of brimonidine timolol for topical ophthalmic use |
19 Apr, 2022
(3 years ago)
| Expired |
| US7320976 | Combination of brimonidine and timolol for topical ophthalmic use |
19 Apr, 2022
(3 years ago)
| Expired |
| US7642258 | Combination of brimonidine and timolol for topical ophthalmic use |
19 Apr, 2022
(3 years ago)
| Expired |
| US8133890 | Combination of brimonidine and timolol for topical ophthalmic use |
19 Apr, 2022
(3 years ago)
| Expired |
| US8354409 | Combination of brimonidine and timolol for topical ophthalmic use |
19 Apr, 2022
(3 years ago)
| Expired |
| US8748425 | Combination of brimonidine and timolol for topical ophthalmic use |
19 Apr, 2022
(3 years ago)
| Expired |
| US9474751 | Combination of brimonidine and timolol for topical ophthalmic use |
19 Apr, 2022
(3 years ago)
| Expired |
| US9770453 | Combination of brimonidine and timolol for topical ophthalmic use |
19 Apr, 2022
(3 years ago)
| Expired |
| US9907801 | Combination of brimonidine and timolol for topical ophthalmic use |
19 Apr, 2022
(3 years ago)
| Expired |
| US9907802 | Combination of brimonidine and timolol for topical ophthalmic use |
19 Apr, 2022
(3 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Combigan's drug page
13. Creon
Creon is protected by 1 patent, which is still active. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9198871 | Delayed release pancreatin compositions |
07 Feb, 2030
(4 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Creon's drug page
14. Crinone
Crinone is protected by 1 patent, which has expired already. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5543150 | Method of progesterone delivery and affect thereof |
15 Sep, 2013
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Crinone's drug page
15. Dalvance
Dalvance is protected by 4 patents, out of which 3 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6900175 | Methods of administering dalbavancin for treatment of bacterial infections |
23 May, 2028
(2 years from now)
| Active |
| US7115564 | Stable pharmaceutical compositions of dalbavancin and methods of administration |
14 Nov, 2023
(1 year, 7 months ago)
| Expired |
| US7119061 | Dalbavancin compositions for treatment of bacterial infections |
14 Nov, 2023
(1 year, 7 months ago)
| Expired |
| US8143212 | Dalbavancin compositions for treatment of bacterial infections |
14 Nov, 2023
(1 year, 7 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Dalvance's drug page
16. Delzicol
Delzicol is protected by 3 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6649180 | Hard capsule formed of cellulose ether film with a specific content of methoxyl and hydroxypropoxyl groups |
13 Apr, 2020
(5 years ago)
| Expired |
| US5541170 | Orally administrable pharmaceutical compositions |
30 Jul, 2013
(11 years ago)
| Expired |
| US5541171 | Orally administrable pharmaceutical composition |
30 Jul, 2013
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Delzicol's drug page
17. Depakote Er
Depakote Er is protected by 12 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6419953
(Pediatric)
| Controlled release formulation of divalproex sodium |
18 Jun, 2019
(6 years ago)
| Expired |
| US6511678
(Pediatric)
| Controlled release formulation of divalproex sodium |
18 Jun, 2019
(6 years ago)
| Expired |
| US6528090
(Pediatric)
| Controlled release formulation of divalproex sodium |
18 Jun, 2019
(6 years ago)
| Expired |
| US6528091
(Pediatric)
| Controlled release formulation of divalproex sodium |
18 Jun, 2019
(6 years ago)
| Expired |
| US6713086
(Pediatric)
| Controlled release formulation of divalproex sodium |
18 Jun, 2019
(6 years ago)
| Expired |
| US6720004
(Pediatric)
| Controlled release formulation of divalproex sodium |
18 Jun, 2019
(6 years ago)
| Expired |
| US6419953 | Controlled release formulation of divalproex sodium |
18 Dec, 2018
(6 years ago)
| Expired |
| US6511678 | Controlled release formulation of divalproex sodium |
18 Dec, 2018
(6 years ago)
| Expired |
| US6528090 | Controlled release formulation of divalproex sodium |
18 Dec, 2018
(6 years ago)
| Expired |
| US6528091 | Controlled release formulation of divalproex sodium |
18 Dec, 2018
(6 years ago)
| Expired |
| US6713086 | Controlled release formulation of divalproex sodium |
18 Dec, 2018
(6 years ago)
| Expired |
| US6720004 | Controlled release formulation of divalproex sodium |
18 Dec, 2018
(6 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Depakote Er's drug page
18. Durysta
Durysta is protected by 10 patents, out of which 3 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9492316 | Prostamide-containing intraocular implants and methods of use thereof |
31 Oct, 2034
(9 years from now)
| Active |
| US9980974 | Prostamide-containing intraocular implants and methods of use thereof |
31 Oct, 2034
(9 years from now)
| Active |
| US8629185 | 7-[3,5-dihydroxy-2- (3-hydroxy-5-phenyl-pent-1-enyl)-cyclopentyl]-N-ethyl-hept-5-enamide (bimatoprost) in crystalline form II, methods for preparation, and methods for use thereof |
15 Jul, 2031
(6 years from now)
| Active |
| US7799336 | Hypotensive lipid-containing biodegradable intraocular implants and related methods |
24 Apr, 2029
(3 years from now)
| Active |
| US8206737 | Hypotensive lipid-containing biodegradable intraocular implants and related methods |
07 Apr, 2027
(1 year, 9 months from now)
| Active |
| US10441543 | Processes for making cyclic lipid implants for intraocular use |
19 Dec, 2026
(1 year, 5 months from now)
| Active |
| US9149428 | Processes for making cyclic lipid implants for intraocular use |
19 Dec, 2026
(1 year, 5 months from now)
| Active |
| US8673341 | Intraocular pressure reduction with intracameral bimatoprost implants |
19 Feb, 2025
(4 months ago)
| Expired |
| US10398707 | Hypotensive lipid-containing biodegradable intraocular implants and related implants |
30 Apr, 2024
(1 year, 2 months ago)
| Expired |
| US7033605 | Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor |
20 Oct, 2020
(4 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Durysta's drug page
19. Emblaveo
Emblaveo is protected by 7 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8969566 | Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof |
15 Jun, 2032
(6 years from now)
| Active |
| US9284314 | Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof |
15 Jun, 2032
(6 years from now)
| Active |
| US9695122 | Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof |
15 Jun, 2032
(6 years from now)
| Active |
| US8471025 | Crystalline forms of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide sodium salt |
12 Aug, 2031
(6 years from now)
| Active |
| US8835455 | Crystalline forms of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide sodium salt |
08 Oct, 2030
(5 years from now)
| Active |
| US7612087 | Heterocyclic compounds as inhibitors of beta-lactamases |
12 Nov, 2026
(1 year, 4 months from now)
| Active |
| US7112592 | Azabicyclic compounds, preparation thereof and use as medicines, in particular as antibacterial agents |
07 Jan, 2026
(6 months from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Emblaveo's drug page
20. Enablex
Enablex is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6106864 | Pharmaceutical formulations containing darifenacin |
21 Aug, 2016
(8 years ago)
| Expired |
| US5096890 | Pyrrolidine derivatives |
13 Mar, 2015
(10 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Enablex's drug page
21. Fetzima
Fetzima is protected by 3 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8865937 | Crystalline forms of (1S,2R)-2-(amino methyl)-N,N-diethyl-1-phenyl cyclopropane carboxamide |
23 May, 2032
(6 years from now)
| Active |
| US8481598 | Stable dosage forms of levomilnacipran |
02 Mar, 2031
(5 years from now)
| Active |
| USRE43879 | Use of the dextrogyral enantiomer of milnacipran for the preparation of a drug |
11 Jan, 2026
(6 months from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Fetzima's drug page
22. Gelnique
Gelnique is protected by 7 patents, out of which 4 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8920392 | Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions |
26 Mar, 2031
(5 years from now)
| Active |
| US10449173 | Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions |
06 Nov, 2029
(4 years from now)
| Active |
| US9259388 | Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions |
06 Nov, 2029
(4 years from now)
| Active |
| US10272061 | Compositions and methods for unoccluded transdermal oxybutynin therapy |
26 Apr, 2020
(5 years ago)
| Expired |
| US7029694 | Compositions and methods for transdermal oxybutynin therapy |
26 Apr, 2020
(5 years ago)
| Expired |
| US7179483 | Compositions and methods for transdermal oxybutynin therapy |
26 Apr, 2020
(5 years ago)
| Expired |
| US8241662 | Unoccluded topical oxybutynin gel composition and methods for transdermal oxybutynin therapy |
26 Apr, 2020
(5 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Gelnique's drug page
23. Kaletra
Kaletra is protected by 49 patents, out of which 43 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8025899
(Pediatric)
| Solid pharmaceutical dosage form |
14 Jun, 2028
(2 years from now)
| Active |
| US8377952
(Pediatric)
| Solid pharmaceutical dosage formulation |
22 Apr, 2028
(2 years from now)
| Active |
| US8025899 | Solid pharmaceutical dosage form |
14 Dec, 2027
(2 years from now)
| Active |
| US8377952 | Solid pharmaceutical dosage formulation |
22 Oct, 2027
(2 years from now)
| Active |
| US8470347
(Pediatric)
| Self-emulsifying active substance formulation and use of this formulation |
17 Mar, 2027
(1 year, 8 months from now)
| Active |
| US8470347 | Self-emulsifying active substance formulation and use of this formulation |
17 Sep, 2026
(1 year, 2 months from now)
| Active |
| US8309613
(Pediatric)
| Solid pharmaceutical dosage form |
24 Jun, 2025
(8 days ago)
| Expired |
| US8268349
(Pediatric)
| Solid pharmaceutical dosage form |
25 Feb, 2025
(4 months ago)
| Expired |
| US8399015
(Pediatric)
| Solid pharmaceutical dosage form |
25 Feb, 2025
(4 months ago)
| Expired |
| US8691878
(Pediatric)
| Solid pharmaceutical dosage form |
25 Feb, 2025
(4 months ago)
| Expired |
| US8309613 | Solid pharmaceutical dosage form |
24 Dec, 2024
(6 months ago)
| Expired |
| US8268349 | Solid pharmaceutical dosage form |
25 Aug, 2024
(10 months ago)
| Expired |
| US8399015 | Solid pharmaceutical dosage form |
25 Aug, 2024
(10 months ago)
| Expired |
| US8691878 | Solid pharmaceutical dosage form |
25 Aug, 2024
(10 months ago)
| Expired |
| US6911214
(Pediatric)
| Flavoring systems for pharmaceutical compositions and methods of making such compositions |
28 May, 2022
(3 years ago)
| Expired |
| US6911214 | Flavoring systems for pharmaceutical compositions and methods of making such compositions |
28 Nov, 2021
(3 years ago)
| Expired |
| US8501219 | Flavoring systems for pharmaceutical compositions and methods of making such compositions |
28 Nov, 2021
(3 years ago)
| Expired |
| US7364752
(Pediatric)
| Solid dispersion pharamaceutical formulations |
10 May, 2021
(4 years ago)
| Expired |
| US7141593
(Pediatric)
| Pharmaceutical formulations |
22 Nov, 2020
(4 years ago)
| Expired |
| US7432294
(Pediatric)
| Pharmaceutical formulations |
22 Nov, 2020
(4 years ago)
| Expired |
| US7364752 | Solid dispersion pharamaceutical formulations |
10 Nov, 2020
(4 years ago)
| Expired |
| US7141593 | Pharmaceutical formulations |
22 May, 2020
(5 years ago)
| Expired |
| US7432294 | Pharmaceutical formulations |
22 May, 2020
(5 years ago)
| Expired |
| US7148359
(Pediatric)
| Polymorph of a pharmaceutical |
19 Jan, 2020
(5 years ago)
| Expired |
| US7148359 | Polymorph of a pharmaceutical |
19 Jul, 2019
(5 years ago)
| Expired |
| US6232333
(Pediatric)
| Pharmaceutical composition |
07 May, 2018
(7 years ago)
| Expired |
| US6458818
(Pediatric)
| Pharmaceutical composition |
07 May, 2018
(7 years ago)
| Expired |
| US6521651
(Pediatric)
| Pharmaceutical composition |
07 May, 2018
(7 years ago)
| Expired |
| US6232333 | Pharmaceutical composition |
07 Nov, 2017
(7 years ago)
| Expired |
| US6458818 | Pharmaceutical composition |
07 Nov, 2017
(7 years ago)
| Expired |
| US6521651 | Pharmaceutical composition |
07 Nov, 2017
(7 years ago)
| Expired |
| US6037157
(Pediatric)
| Method for improving pharmacokinetics |
26 Dec, 2016
(8 years ago)
| Expired |
| US6703403
(Pediatric)
| Method for improving pharmacokinetics |
26 Dec, 2016
(8 years ago)
| Expired |
| US6284767
(Pediatric)
| Retroviral protease inhibiting compounds |
15 Aug, 2016
(8 years ago)
| Expired |
| US6037157 | Method for improving pharmacokinetics |
26 Jun, 2016
(9 years ago)
| Expired |
| US6703403 | Method for improving pharmacokinetics |
26 Jun, 2016
(9 years ago)
| Expired |
| US5914332
(Pediatric)
| Retroviral protease inhibiting compounds |
13 Jun, 2016
(9 years ago)
| Expired |
| US6284767 | Retroviral protease inhibiting compounds |
15 Feb, 2016
(9 years ago)
| Expired |
| US5914332 | Retroviral protease inhibiting compounds |
13 Dec, 2015
(9 years ago)
| Expired |
| US5648497
(Pediatric)
| Retroviral protease inhibiting compounds |
15 Jan, 2015
(10 years ago)
| Expired |
| US5484801
(Pediatric)
| Pharmaceutical composition for inhibiting HIV protease |
28 Jul, 2014
(10 years ago)
| Expired |
| US5648497 | Retroviral protease inhibiting compounds |
15 Jul, 2014
(10 years ago)
| Expired |
| US5886036
(Pediatric)
| Retroviral protease inhibiting compounds |
19 May, 2014
(11 years ago)
| Expired |
| US5948436
(Pediatric)
| Pharmaceutical composition |
13 Mar, 2014
(11 years ago)
| Expired |
| US5541206
(Pediatric)
| Retroviral protease inhibiting compounds |
30 Jan, 2014
(11 years ago)
| Expired |
| US5484801 | Pharmaceutical composition for inhibiting HIV protease |
28 Jan, 2014
(11 years ago)
| Expired |
| US5886036 | Retroviral protease inhibiting compounds |
19 Nov, 2013
(11 years ago)
| Expired |
| US5948436 | Pharmaceutical composition |
13 Sep, 2013
(11 years ago)
| Expired |
| US5541206 | Retroviral protease inhibiting compounds |
30 Jul, 2013
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Kaletra's drug page
24. Kybella
Kybella is protected by 16 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12161653 | Treatment of submental fat |
17 Feb, 2032
(6 years from now)
| Active |
| US10500214 | Formulations of deoxycholic acid and salts thereof |
02 Mar, 2030
(4 years from now)
| Active |
| US8101593 | Formulations of deoxycholic acid and salts thereof |
02 Mar, 2030
(4 years from now)
| Active |
| US8367649 | Formulations of deoxycholic acid and salts thereof |
02 Mar, 2030
(4 years from now)
| Active |
| US8653058 | Compositions comprising deoxycholic acid and salts thereof suitable for use in treating fat deposits |
02 Mar, 2030
(4 years from now)
| Active |
| US8242294 | Synthetic bile acid compositions and methods |
16 May, 2028
(2 years from now)
| Active |
| US8461140 | Synthetic bile acid compositions and methods |
21 Feb, 2028
(2 years from now)
| Active |
| US8546367 | Synthetic bile acid compositions and methods |
21 Feb, 2028
(2 years from now)
| Active |
| US8883770 | Synthetic bile acid compositions and methods |
21 Feb, 2028
(2 years from now)
| Active |
| US9522155 | Synthetic bile acid compositions and methods |
21 Feb, 2028
(2 years from now)
| Active |
| US9636349 | Synthetic bile acid compositions and methods |
21 Feb, 2028
(2 years from now)
| Active |
| US9949986 | Synthetic bile acid compositions and methods |
21 Feb, 2028
(2 years from now)
| Active |
| US7622130 | Methods and compositions for the non-surgical removal of fat |
10 Dec, 2027
(2 years from now)
| Active |
| US7754230 | Methods and related compositions for reduction of fat |
10 Dec, 2027
(2 years from now)
| Active |
| US8298556 | Methods and related compositions for the non-surgical removal of fat |
03 Aug, 2025
(a month from now)
| Active |
| US8846066 | Methods and related compositions for reduction of fat and skin tightening |
08 Feb, 2025
(4 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Kybella's drug page
25. Lastacaft
Lastacaft is protected by 3 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8664215 | Ocular allergy treatments with alcaftadine |
23 Dec, 2027
(2 years from now)
| Active |
| US10617695 | Ophthalmic compositions containing alcaftadine |
19 Mar, 2027
(1 year, 8 months from now)
| Active |
| US5468743 | Imidazo[2,1-b]benzazepine derivatives, compositions and method of use |
21 Nov, 2013
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Lastacaft's drug page
26. Latisse
Latisse is protected by 16 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7351404 | Method of enhancing hair growth |
25 May, 2024
(1 year, 1 month ago)
| Expired |
| US8101161 | Method of enhancing hair growth |
25 May, 2024
(1 year, 1 month ago)
| Expired |
| US8038988 | Method of enhancing hair growth |
25 Aug, 2023
(1 year, 10 months ago)
| Expired |
| US8263054 | Method of enhancing hair growth |
25 Aug, 2023
(1 year, 10 months ago)
| Expired |
| US8632760 | Method of enhancing hair growth |
15 Jan, 2023
(2 years ago)
| Expired |
| US8758733 | Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists |
15 Jan, 2023
(2 years ago)
| Expired |
| US8926953 | Method of enhancing hair growth |
15 Jan, 2023
(2 years ago)
| Expired |
| US8986715 | Method of enhancing hair growth |
15 Jan, 2023
(2 years ago)
| Expired |
| US9216183 | Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists |
15 Jan, 2023
(2 years ago)
| Expired |
| US9226931 | Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists |
15 Jan, 2023
(2 years ago)
| Expired |
| US7388029 | Compositions and methods for treating hair loss using non-naturally occurring prostaglandins |
21 Jan, 2022
(3 years ago)
| Expired |
| US8541466 | Compositions and methods for treating hair loss using non-naturally occurring prostaglandins |
31 Jan, 2021
(4 years ago)
| Expired |
| US8906962 | Compositions and methods for treating hair loss using non-naturally occurring prostaglandins |
31 Jan, 2021
(4 years ago)
| Expired |
| US9579270 | Compositions and methods for treating hair loss using non-naturally occurring prostaglandins |
31 Jan, 2021
(4 years ago)
| Expired |
| US8017655 | Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents |
27 Nov, 2012
(12 years ago)
| Expired |
| US6403649 | Non-acidic cyclopentane heptanoic acid,2-cycloalkyl or arylalkyl derivatives as therapeutic agents |
21 Sep, 2012
(12 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Latisse's drug page
27. Lexapro
Lexapro is protected by 4 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6916941
(Pediatric)
| Crystalline composition containing escitalopram |
12 Feb, 2023
(2 years ago)
| Expired |
| US7420069
(Pediatric)
| Crystalline composition containing escitalopram |
12 Feb, 2023
(2 years ago)
| Expired |
| US6916941 | Crystalline composition containing escitalopram |
12 Aug, 2022
(2 years ago)
| Expired |
| US7420069 | Crystalline composition containing escitalopram |
12 Aug, 2022
(2 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Lexapro's drug page
28. Linzess
Linzess is protected by 12 patents, out of which 5 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9708371 | Treatments for gastrointestinal disorders |
16 Aug, 2033
(8 years from now)
| Active |
| US8748573 | Formulations comprising linaclotide |
30 Oct, 2031
(6 years from now)
| Active |
| US8802628 | Stable solid formulation of a GC-C receptor agonist polypeptide suitable for oral administration |
30 Oct, 2031
(6 years from now)
| Active |
| US10675325 | Stable formulations of linaclotide |
11 Aug, 2031
(6 years from now)
| Active |
| US10702576 | Stable formulations of linaclotide |
11 Aug, 2031
(6 years from now)
| Active |
| US8933030 | Treatments for gastrointestinal disorders |
17 Feb, 2031
(5 years from now)
| Active |
| US7304036 | Methods and compositions for the treatment of gastrointestinal disorders |
30 Aug, 2026
(1 year, 1 month from now)
| Active |
| US7371727 | Methods and compositions for the treatment of gastrointestinal disorders |
28 Jan, 2024
(1 year, 5 months ago)
| Expired |
| US7704947 | Methods and compositions for the treatment of gastrointestinal disorders |
28 Jan, 2024
(1 year, 5 months ago)
| Expired |
| US7745409 | Methods and compositions for the treatment of gastrointestinal disorders |
28 Jan, 2024
(1 year, 5 months ago)
| Expired |
| US8080526 | Methods and compositions for the treatment of gastrointestinal disorders |
28 Jan, 2024
(1 year, 5 months ago)
| Expired |
| US8110553 | Methods and compositions for the treatment of gastrointestinal disorders |
28 Jan, 2024
(1 year, 5 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Linzess's drug page
29. Lumigan
Lumigan is protected by 15 patents, out of which 14 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7851504 | Enhanced bimatoprost ophthalmic solution |
13 Jun, 2027
(1 year, 11 months from now)
| Active |
| US8278353 | Enhanced bimatoprost ophthalmic solution |
16 Mar, 2025
(3 months ago)
| Expired |
| US8299118 | Enhanced bimatoprost ophthalmic solution |
16 Mar, 2025
(3 months ago)
| Expired |
| US8309605 | Enhanced bimatoprost ophthalmic solution |
16 Mar, 2025
(3 months ago)
| Expired |
| US8338479 | Enhanced bimatoprost ophthalmic solution |
16 Mar, 2025
(3 months ago)
| Expired |
| US8524777 | Enhanced bimatoprost ophthalmic solution |
16 Mar, 2025
(3 months ago)
| Expired |
| US8586630 | Enhanced bimatoprost ophthalmic solution |
16 Mar, 2025
(3 months ago)
| Expired |
| US8772338 | Enhanced bimatoprost ophthalmic solution |
16 Mar, 2025
(3 months ago)
| Expired |
| US8933120 | Enhanced bimatoprost ophthalmic solution |
16 Mar, 2025
(3 months ago)
| Expired |
| US8933127 | Enhanced bimatoprost ophthalmic solution |
16 Mar, 2025
(3 months ago)
| Expired |
| US9155716 | Enhanced bimatoprost ophthalmic solution |
16 Mar, 2025
(3 months ago)
| Expired |
| US9241918 | Enhanced bimatoprost ophthalmic solution |
16 Mar, 2025
(3 months ago)
| Expired |
| US5688819 | Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents |
19 Aug, 2014
(10 years ago)
| Expired |
| US8017655 | Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents |
27 Nov, 2012
(12 years ago)
| Expired |
| US6403649 | Non-acidic cyclopentane heptanoic acid,2-cycloalkyl or arylalkyl derivatives as therapeutic agents |
21 Sep, 2012
(12 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Lumigan's drug page
30. Mavik
Mavik is protected by 1 patent, which has expired already. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5744496 | Method of treating cardiac insufficiency using angiotensin-converting enzyme inhibitors |
28 Apr, 2015
(10 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Mavik's drug page
31. Mavyret
Mavyret is protected by 20 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11246866
(Pediatric)
| Solid pharmaceutical compositions for treating HCV |
24 Dec, 2036
(11 years from now)
| Active |
| US11246866 | Solid pharmaceutical compositions for treating HCV |
24 Jun, 2036
(10 years from now)
| Active |
| US9321807
(Pediatric)
| Crystal forms |
05 Dec, 2035
(10 years from now)
| Active |
| USRE48923
(Pediatric)
| Crystal forms |
08 Nov, 2035
(10 years from now)
| Active |
| US9321807 | Crystal forms |
05 Jun, 2035
(9 years from now)
| Active |
| USRE48923 | Crystal forms |
08 May, 2035
(9 years from now)
| Active |
| US10286029
(Pediatric)
| Method for treating HCV |
14 Sep, 2034
(9 years from now)
| Active |
| US11484534
(Pediatric)
| Methods for treating HCV |
14 Sep, 2034
(9 years from now)
| Active |
| US10286029 | Method for treating HCV |
14 Mar, 2034
(8 years from now)
| Active |
| US11484534 | Methods for treating HCV |
14 Mar, 2034
(8 years from now)
| Active |
| US8937150
(Pediatric)
| Anti-viral compounds |
18 Nov, 2032
(7 years from now)
| Active |
| US8648037
(Pediatric)
| Macrocyclic proline derived HCV serine protease inhibitors |
19 Jul, 2032
(7 years from now)
| Active |
| US8937150 | Anti-viral compounds |
18 May, 2032
(6 years from now)
| Active |
| US8648037 | Macrocyclic proline derived HCV serine protease inhibitors |
19 Jan, 2032
(6 years from now)
| Active |
| US9586978
(Pediatric)
| Anti-viral compounds |
06 May, 2031
(5 years from now)
| Active |
| US10028937
(Pediatric)
| Anti-viral compounds |
10 Dec, 2030
(5 years from now)
| Active |
| US10039754
(Pediatric)
| Anti-viral compounds |
10 Dec, 2030
(5 years from now)
| Active |
| US9586978 | Anti-viral compounds |
06 Nov, 2030
(5 years from now)
| Active |
| US10028937 | Anti-viral compounds |
10 Jun, 2030
(4 years from now)
| Active |
| US10039754 | Anti-viral compounds |
10 Jun, 2030
(4 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Mavyret's drug page
32. Namenda
Namenda is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5061703
(Pediatric)
| Adamantane derivatives in the prevention and treatment of cerebral ischemia |
11 Oct, 2015
(9 years ago)
| Expired |
| US5061703 | Adamantane derivatives in the prevention and treatment of cerebral ischemia |
11 Apr, 2015
(10 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Namenda's drug page
33. Namenda Xr
Namenda Xr is protected by 16 patents, out of which 2 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8039009
(Pediatric)
| Modified release formulations of memantine oral dosage forms |
24 Sep, 2029
(4 years from now)
| Active |
| US8039009 | Modified release formulations of memantine oral dosage forms |
24 Mar, 2029
(3 years from now)
| Active |
| US8168209
(Pediatric)
| Method and composition for administering an NMDA receptor antagonist to a subject |
22 May, 2026
(10 months from now)
| Active |
| US8173708
(Pediatric)
| Method and composition for administering an NMDA receptor antagonist to a subject |
22 May, 2026
(10 months from now)
| Active |
| US8283379
(Pediatric)
| Methods and compositions for the treatment of CNS-related conditions |
22 May, 2026
(10 months from now)
| Active |
| US8329752
(Pediatric)
| Composition for administering an NMDA receptor antagonist to a subject |
22 May, 2026
(10 months from now)
| Active |
| US8362085
(Pediatric)
| Method for administering an NMDA receptor antagonist to a subject |
22 May, 2026
(10 months from now)
| Active |
| US8598233
(Pediatric)
| Method for administering an NMDA receptor antagonist to a subject |
22 May, 2026
(10 months from now)
| Active |
| US8168209 | Method and composition for administering an NMDA receptor antagonist to a subject |
22 Nov, 2025
(4 months from now)
| Active |
| US8173708 | Method and composition for administering an NMDA receptor antagonist to a subject |
22 Nov, 2025
(4 months from now)
| Active |
| US8283379 | Methods and compositions for the treatment of CNS-related conditions |
22 Nov, 2025
(4 months from now)
| Active |
| US8329752 | Composition for administering an NMDA receptor antagonist to a subject |
22 Nov, 2025
(4 months from now)
| Active |
| US8362085 | Method for administering an NMDA receptor antagonist to a subject |
22 Nov, 2025
(4 months from now)
| Active |
| US8598233 | Method for administering an NMDA receptor antagonist to a subject |
22 Nov, 2025
(4 months from now)
| Active |
| US5061703
(Pediatric)
| Adamantane derivatives in the prevention and treatment of cerebral ischemia |
11 Oct, 2015
(9 years ago)
| Expired |
| US5061703 | Adamantane derivatives in the prevention and treatment of cerebral ischemia |
11 Apr, 2015
(10 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Namenda Xr's drug page
34. Namzaric
Namzaric is protected by 21 patents, out of which 2 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8058291 | Methods and compositions for the treatment of CNS-related conditions |
05 Dec, 2029
(4 years from now)
| Active |
| US8039009
(Pediatric)
| Modified release formulations of memantine oral dosage forms |
24 Sep, 2029
(4 years from now)
| Active |
| US8039009 | Modified release formulations of memantine oral dosage forms |
24 Mar, 2029
(3 years from now)
| Active |
| US8168209
(Pediatric)
| Method and composition for administering an NMDA receptor antagonist to a subject |
22 May, 2026
(10 months from now)
| Active |
| US8173708
(Pediatric)
| Method and composition for administering an NMDA receptor antagonist to a subject |
22 May, 2026
(10 months from now)
| Active |
| US8283379
(Pediatric)
| Methods and compositions for the treatment of CNS-related conditions |
22 May, 2026
(10 months from now)
| Active |
| US8329752
(Pediatric)
| Composition for administering an NMDA receptor antagonist to a subject |
22 May, 2026
(10 months from now)
| Active |
| US8362085
(Pediatric)
| Method for administering an NMDA receptor antagonist to a subject |
22 May, 2026
(10 months from now)
| Active |
| US8598233
(Pediatric)
| Method for administering an NMDA receptor antagonist to a subject |
22 May, 2026
(10 months from now)
| Active |
| US8168209 | Method and composition for administering an NMDA receptor antagonist to a subject |
22 Nov, 2025
(4 months from now)
| Active |
| US8173708 | Method and composition for administering an NMDA receptor antagonist to a subject |
22 Nov, 2025
(4 months from now)
| Active |
| US8283379 | Methods and compositions for the treatment of CNS-related conditions |
22 Nov, 2025
(4 months from now)
| Active |
| US8293794 | Methods and compositions for the treatment of CNS-related conditions |
22 Nov, 2025
(4 months from now)
| Active |
| US8329752 | Composition for administering an NMDA receptor antagonist to a subject |
22 Nov, 2025
(4 months from now)
| Active |
| US8338485 | Compositions for the treatment of CNS-related conditions |
22 Nov, 2025
(4 months from now)
| Active |
| US8338486 | Methods for the treatment of CNS-related conditions |
22 Nov, 2025
(4 months from now)
| Active |
| US8362085 | Method for administering an NMDA receptor antagonist to a subject |
22 Nov, 2025
(4 months from now)
| Active |
| US8580858 | Compositions for the treatment of CNS-related conditions |
22 Nov, 2025
(4 months from now)
| Active |
| US8598233 | Method for administering an NMDA receptor antagonist to a subject |
22 Nov, 2025
(4 months from now)
| Active |
| US5061703
(Pediatric)
| Adamantane derivatives in the prevention and treatment of cerebral ischemia |
11 Oct, 2015
(9 years ago)
| Expired |
| US5061703 | Adamantane derivatives in the prevention and treatment of cerebral ischemia |
11 Apr, 2015
(10 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Namzaric's drug page
35. Niaspan
Niaspan is protected by 10 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6469035 | Methods of pretreating hyperlipidemic individuals with a flush inhibiting agent prior to the start of single daily dose nicotinic acid therapy to reduce flushing provoked by nicotinic acid |
15 Mar, 2018
(7 years ago)
| Expired |
| US6080428 | Nicotinic acid compositions for treating hyperlipidemia and related methods therefor |
27 May, 2017
(8 years ago)
| Expired |
| US6818229 | Intermediate release nicotinic acid compositions for treating hyperlipidemia |
15 Feb, 2014
(11 years ago)
| Expired |
| US6129930 | Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night |
20 Sep, 2013
(11 years ago)
| Expired |
| US6406715 | Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique urinary metabolite profiles |
20 Sep, 2013
(11 years ago)
| Expired |
| US6676967 | Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia |
20 Sep, 2013
(11 years ago)
| Expired |
| US6746691 | Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics |
20 Sep, 2013
(11 years ago)
| Expired |
| US6818229 | Intermediate release nicotinic acid compositions for treating hyperlipidemia |
20 Sep, 2013
(11 years ago)
| Expired |
| US7011848 | Hydrophobic component free sustained release nicotinic acid compositions for treating hyperlipidemia and related methods therefor |
20 Sep, 2013
(11 years ago)
| Expired |
| US7998506 | Nicotinic acid compositions for treating hyperlipidemia and related methods therefor |
20 Sep, 2013
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Niaspan's drug page
36. Niaspan Titration Starter Pack
Niaspan Titration Starter Pack is protected by 5 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6080428 | Nicotinic acid compositions for treating hyperlipidemia and related methods therefor |
27 May, 2017
(8 years ago)
| Expired |
| US6129930 | Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night |
20 Sep, 2013
(11 years ago)
| Expired |
| US6406715 | Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique urinary metabolite profiles |
20 Sep, 2013
(11 years ago)
| Expired |
| US6746691 | Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics |
20 Sep, 2013
(11 years ago)
| Expired |
| US7011848 | Hydrophobic component free sustained release nicotinic acid compositions for treating hyperlipidemia and related methods therefor |
20 Sep, 2013
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Niaspan Titration Starter Pack's drug page
37. Nimbex
Nimbex is protected by 1 patent, which has expired already. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5453510 | Neuromuscular blocking agents |
26 Sep, 2012
(12 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Nimbex's drug page
38. Nimbex Preservative Free
Nimbex Preservative Free is protected by 1 patent, which has expired already. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5453510 | Neuromuscular blocking agents |
26 Sep, 2012
(12 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Nimbex Preservative Free's drug page
39. Norvir
Norvir is protected by 34 patents, out of which 32 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8470347
(Pediatric)
| Self-emulsifying active substance formulation and use of this formulation |
17 Mar, 2027
(1 year, 8 months from now)
| Active |
| US8470347 | Self-emulsifying active substance formulation and use of this formulation |
17 Sep, 2026
(1 year, 2 months from now)
| Active |
| US8268349
(Pediatric)
| Solid pharmaceutical dosage form |
25 Feb, 2025
(4 months ago)
| Expired |
| US8399015
(Pediatric)
| Solid pharmaceutical dosage form |
25 Feb, 2025
(4 months ago)
| Expired |
| US8691878
(Pediatric)
| Solid pharmaceutical dosage form |
25 Feb, 2025
(4 months ago)
| Expired |
| US8268349 | Solid pharmaceutical dosage form |
25 Aug, 2024
(10 months ago)
| Expired |
| US8399015 | Solid pharmaceutical dosage form |
25 Aug, 2024
(10 months ago)
| Expired |
| US8691878 | Solid pharmaceutical dosage form |
25 Aug, 2024
(10 months ago)
| Expired |
| US7364752
(Pediatric)
| Solid dispersion pharamaceutical formulations |
10 May, 2021
(4 years ago)
| Expired |
| US7141593
(Pediatric)
| Pharmaceutical formulations |
22 Nov, 2020
(4 years ago)
| Expired |
| US7432294
(Pediatric)
| Pharmaceutical formulations |
22 Nov, 2020
(4 years ago)
| Expired |
| US7364752 | Solid dispersion pharamaceutical formulations |
10 Nov, 2020
(4 years ago)
| Expired |
| US7141593 | Pharmaceutical formulations |
22 May, 2020
(5 years ago)
| Expired |
| US7432294 | Pharmaceutical formulations |
22 May, 2020
(5 years ago)
| Expired |
| US7148359
(Pediatric)
| Polymorph of a pharmaceutical |
19 Jan, 2020
(5 years ago)
| Expired |
| US7148359 | Polymorph of a pharmaceutical |
19 Jul, 2019
(5 years ago)
| Expired |
| US6232333
(Pediatric)
| Pharmaceutical composition |
07 May, 2018
(7 years ago)
| Expired |
| US6232333 | Pharmaceutical composition |
07 Nov, 2017
(7 years ago)
| Expired |
| US6037157
(Pediatric)
| Method for improving pharmacokinetics |
26 Dec, 2016
(8 years ago)
| Expired |
| US6703403
(Pediatric)
| Method for improving pharmacokinetics |
26 Dec, 2016
(8 years ago)
| Expired |
| US6037157 | Method for improving pharmacokinetics |
26 Jun, 2016
(9 years ago)
| Expired |
| US6703403 | Method for improving pharmacokinetics |
26 Jun, 2016
(9 years ago)
| Expired |
| US5648497
(Pediatric)
| Retroviral protease inhibiting compounds |
15 Jan, 2015
(10 years ago)
| Expired |
| US5484801
(Pediatric)
| Pharmaceutical composition for inhibiting HIV protease |
28 Jul, 2014
(10 years ago)
| Expired |
| US5648497 | Retroviral protease inhibiting compounds |
15 Jul, 2014
(10 years ago)
| Expired |
| US5948436
(Pediatric)
| Pharmaceutical composition |
13 Mar, 2014
(11 years ago)
| Expired |
| US5541206
(Pediatric)
| Retroviral protease inhibiting compounds |
30 Jan, 2014
(11 years ago)
| Expired |
| US5635523
(Pediatric)
| Retroviral protease inhibiting compounds |
30 Jan, 2014
(11 years ago)
| Expired |
| US5674882
(Pediatric)
| Retroviral protease inhibiting compounds |
30 Jan, 2014
(11 years ago)
| Expired |
| US5484801 | Pharmaceutical composition for inhibiting HIV protease |
28 Jan, 2014
(11 years ago)
| Expired |
| US5948436 | Pharmaceutical composition |
13 Sep, 2013
(11 years ago)
| Expired |
| US5541206 | Retroviral protease inhibiting compounds |
30 Jul, 2013
(11 years ago)
| Expired |
| US5635523 | Retroviral protease inhibiting compounds |
30 Jul, 2013
(11 years ago)
| Expired |
| US5674882 | Retroviral protease inhibiting compounds |
30 Jul, 2013
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Norvir's drug page
40. Oriahnn (copackaged)
Oriahnn (copackaged) is protected by 11 patents, out of which 4 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11690845 | Methods of administering elagolix |
27 Aug, 2040
(15 years from now)
| Active |
| US11542239 | Elagolix sodium compositions and processes |
23 Jul, 2039
(14 years from now)
| Active |
| US12083227 | Solid pharmaceutical formulations for treating endometriosis, uterine fibroids, polycystic ovary syndrome or adenomyosis |
20 Aug, 2038
(13 years from now)
| Active |
| US10881659 | Methods of treating heavy menstrual bleeding |
14 Mar, 2034
(8 years from now)
| Active |
| US11045470 | Methods of treating heavy menstrual bleeding |
14 Mar, 2034
(8 years from now)
| Active |
| US7419983 | Gonadotropin-releasing hormone receptor antagonists and methods related thereto |
06 Jul, 2029
(4 years from now)
| Active |
| US11459305 | Processes for the preparation of uracil derivatives |
07 Nov, 2028
(3 years from now)
| Active |
| US7056927 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
10 Sep, 2024
(9 months ago)
| Expired |
| US7179815 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
07 Mar, 2021
(4 years ago)
| Expired |
| US6872728 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
25 Jan, 2021
(4 years ago)
| Expired |
| US7462625 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
25 Jan, 2021
(4 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Oriahnn (copackaged)'s drug page
41. Orilissa
Orilissa is protected by 14 patents, out of which 5 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11690845 | Methods of administering elagolix |
27 Aug, 2040
(15 years from now)
| Active |
| US11542239 | Elagolix sodium compositions and processes |
23 Jul, 2039
(14 years from now)
| Active |
| US12102637 | Pharmaceutical formulations for treating endometriosis, uterine fibroids, polycystic ovary syndrome or adenomyosis |
20 Aug, 2038
(13 years from now)
| Active |
| US11690854 | Methods of treating heavy menstrual bleeding |
19 Apr, 2038
(12 years from now)
| Active |
| US10537572 | Methods of administering elagolix |
01 Sep, 2036
(11 years from now)
| Active |
| US10682351 | Methods of administering elagolix |
01 Sep, 2036
(11 years from now)
| Active |
| US11344551 | Methods of treating heavy menstrual bleeding |
14 Mar, 2034
(8 years from now)
| Active |
| US11707464 | Methods of treating heavy menstrual bleeding |
14 Mar, 2034
(8 years from now)
| Active |
| US7419983 | Gonadotropin-releasing hormone receptor antagonists and methods related thereto |
06 Jul, 2029
(4 years from now)
| Active |
| US7056927 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
10 Sep, 2024
(9 months ago)
| Expired |
| US7176211 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
06 Jul, 2024
(11 months ago)
| Expired |
| US7179815 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
07 Mar, 2021
(4 years ago)
| Expired |
| US6872728 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
25 Jan, 2021
(4 years ago)
| Expired |
| US7462625 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
25 Jan, 2021
(4 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Orilissa's drug page
42. Oxytrol For Women
Oxytrol For Women is protected by 8 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6743441 | Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy |
26 Apr, 2020
(5 years ago)
| Expired |
| US7081249 | Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy |
26 Apr, 2020
(5 years ago)
| Expired |
| US7081250 | Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy |
26 Apr, 2020
(5 years ago)
| Expired |
| US7081251 | Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy |
26 Apr, 2020
(5 years ago)
| Expired |
| US7081252 | Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy |
26 Apr, 2020
(5 years ago)
| Expired |
| US7179483 | Compositions and methods for transdermal oxybutynin therapy |
26 Apr, 2020
(5 years ago)
| Expired |
| US5601839 | Triacetin as a penetration enhancer for transdermal delivery of a basic drug |
26 Apr, 2015
(10 years ago)
| Expired |
| US5834010 | Triacetin as a penetration enhancer for transdermal delivery of a basic drug |
26 Apr, 2015
(10 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Oxytrol For Women's drug page
43. Ozurdex
Ozurdex is protected by 17 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6899717 | Methods and apparatus for delivery of ocular implants |
01 Nov, 2023
(1 year, 8 months ago)
| Expired |
| US10076526 | Ocular implant made by a double extrusion process |
09 Jan, 2023
(2 years ago)
| Expired |
| US10702539 | Ocular implant made by a double extrusion process |
09 Jan, 2023
(2 years ago)
| Expired |
| US8034366 | Ocular implant made by a double extrusion process |
09 Jan, 2023
(2 years ago)
| Expired |
| US8034370 | Ocular implant made by a double extrusion process |
09 Jan, 2023
(2 years ago)
| Expired |
| US8506987 | Ocular implant made by a double extrusion process |
09 Jan, 2023
(2 years ago)
| Expired |
| US9192511 | Ocular implant made by a double extrusion process |
09 Jan, 2023
(2 years ago)
| Expired |
| US7767223 | Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use |
28 Nov, 2021
(3 years ago)
| Expired |
| US6726918 | Methods for treating inflammation-mediated conditions of the eye |
20 Oct, 2020
(4 years ago)
| Expired |
| US7033605 | Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor |
20 Oct, 2020
(4 years ago)
| Expired |
| US8043628 | Methods for reducing edema |
20 Oct, 2020
(4 years ago)
| Expired |
| US8063031 | Implants and methods for treating inflammation-mediated conditions of the eye |
20 Oct, 2020
(4 years ago)
| Expired |
| US8088407 | Method for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor |
20 Oct, 2020
(4 years ago)
| Expired |
| US9012437 | Implants and methods for treating inflammation-mediated conditions of the eye |
20 Oct, 2020
(4 years ago)
| Expired |
| US9283178 | Methods for treating edema in the eye and intraocular implants for use therefor |
20 Oct, 2020
(4 years ago)
| Expired |
| US9592242 | Methods for treating edema in the eye and intraocular implants for use therefor |
20 Oct, 2020
(4 years ago)
| Expired |
| US9775849 | Implants and methods for treating inflammation-mediated conditions of the eye |
20 Oct, 2020
(4 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Ozurdex's drug page
44. Qulipta
Qulipta is protected by 5 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12090148 | Treatment of migraine |
29 Jul, 2041
(16 years from now)
| Active |
| US10117836 | Tablet formulation for CGRP active compounds |
30 Jan, 2035
(9 years from now)
| Active |
| US9850246 | Process for making CGRP receptor antagonists |
13 Mar, 2033
(7 years from now)
| Active |
| US8754096 | Piperidinone carboxamide azaindane CGRP receptor antagonists |
19 Jul, 2032
(7 years from now)
| Active |
| US9499545 | Piperidinone carboxamide azaindane CGRP receptor antagonists |
10 Nov, 2031
(6 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Qulipta's drug page
45. Rapaflo
Rapaflo is protected by 4 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5387603 | 1,5,7-trisubstituted indoline compounds and salts thereof |
01 Dec, 2018
(6 years ago)
| Expired |
| US5403847 | Use of α1C specific compounds to treat benign prostatic hyperlasia |
13 Nov, 2012
(12 years ago)
| Expired |
| US5780485 | Use of α1c specific compounds to treat benign prostatic hyperplasia |
13 Nov, 2012
(12 years ago)
| Expired |
| US6015819 | Use of alpha-1C specific compounds to treat benign prostatic hyperplasia |
13 Nov, 2012
(12 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Rapaflo's drug page
46. Rectiv
Rectiv is protected by 1 patent, which has expired already. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7189761 | Nitric oxide donor composition and method for treatment of anal disorders |
27 May, 2014
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Rectiv's drug page
47. Restasis
Restasis is protected by 7 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8629111 | Methods of providing therapeutic effects using cyclosporin components |
27 Aug, 2024
(10 months ago)
| Expired |
| US8633162 | Methods of providing therapeutic effects using cyclosporin components |
27 Aug, 2024
(10 months ago)
| Expired |
| US8642556 | Methods of providing therapeutic effects using cyclosporin components |
27 Aug, 2024
(10 months ago)
| Expired |
| US8648048 | Methods of providing therapeutic effects using cyclosporin components |
27 Aug, 2024
(10 months ago)
| Expired |
| US8685930 | Methods of providing therapeutic effects using cyclosporin components |
27 Aug, 2024
(10 months ago)
| Expired |
| US9248191 | Methods of providing therapeutic effects using cyclosporin components |
27 Aug, 2024
(10 months ago)
| Expired |
| US5474979 | Nonirritating emulsions for sensitive tissue |
17 May, 2014
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Restasis's drug page
48. Restasis Multidose
Restasis Multidose is protected by 10 patents, out of which 6 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9669974 | Protective cap for a dispenser, and discharge device for discharging pharmaceutical and/or cosmetical liquids |
11 May, 2034
(8 years from now)
| Active |
| US9676525 | Protective cap for a dispenser, and discharge device for discharging pharmaceutical and/or cosmetical liquids |
07 Feb, 2034
(8 years from now)
| Active |
| US8561859 | Dispensing device |
16 Apr, 2032
(6 years from now)
| Active |
| US8292129 | Dispensing device |
25 Feb, 2031
(5 years from now)
| Active |
| US8629111 | Methods of providing therapeutic effects using cyclosporin components |
27 Aug, 2024
(10 months ago)
| Expired |
| US8633162 | Methods of providing therapeutic effects using cyclosporin components |
27 Aug, 2024
(10 months ago)
| Expired |
| US8642556 | Methods of providing therapeutic effects using cyclosporin components |
27 Aug, 2024
(10 months ago)
| Expired |
| US8648048 | Methods of providing therapeutic effects using cyclosporin components |
27 Aug, 2024
(10 months ago)
| Expired |
| US8685930 | Methods of providing therapeutic effects using cyclosporin components |
27 Aug, 2024
(10 months ago)
| Expired |
| US9248191 | Methods of providing therapeutic effects using cyclosporin components |
27 Aug, 2024
(10 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Restasis Multidose's drug page
49. Rinvoq
Rinvoq is protected by 43 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11564922 | Methods of treating crohn's disease and ulcerative colitis |
09 Mar, 2038
(12 years from now)
| Active |
| US11607411 | Methods of treating Crohn's disease and ulcerative colitis |
09 Mar, 2038
(12 years from now)
| Active |
| US10202393 | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-α]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
17 Oct, 2036
(11 years from now)
| Active |
| US10344036 | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-#a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-#carboxamide and solid state forms thereof |
17 Oct, 2036
(11 years from now)
| Active |
| US10519164 | Processes for the preparation of (3S,4R)-3,ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
17 Oct, 2036
(11 years from now)
| Active |
| US10550126 | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
17 Oct, 2036
(11 years from now)
| Active |
| US10597400 | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carb oxamide and solid state forms thereof |
17 Oct, 2036
(11 years from now)
| Active |
| US10730883 | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
17 Oct, 2036
(11 years from now)
| Active |
| US10981923 | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[l,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
17 Oct, 2036
(11 years from now)
| Active |
| US10981924 | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
17 Oct, 2036
(11 years from now)
| Active |
| US10995095 | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carb oxamide and solid state forms thereof |
17 Oct, 2036
(11 years from now)
| Active |
| US11186584 | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
17 Oct, 2036
(11 years from now)
| Active |
| US11198697 | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
17 Oct, 2036
(11 years from now)
| Active |
| US11365198 | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
17 Oct, 2036
(11 years from now)
| Active |
| US11512092 | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
17 Oct, 2036
(11 years from now)
| Active |
| US11524964 | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
17 Oct, 2036
(11 years from now)
| Active |
| US11535624 | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-α]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
17 Oct, 2036
(11 years from now)
| Active |
| US11535625 | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
17 Oct, 2036
(11 years from now)
| Active |
| US11535626 | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1 carboxamide and solid state forms thereof |
17 Oct, 2036
(11 years from now)
| Active |
| US11661425 | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
17 Oct, 2036
(11 years from now)
| Active |
| US11680069 | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
17 Oct, 2036
(11 years from now)
| Active |
| US11718627 | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
17 Oct, 2036
(11 years from now)
| Active |
| US11767326 | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
17 Oct, 2036
(11 years from now)
| Active |
| US11773105 | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]- pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
17 Oct, 2036
(11 years from now)
| Active |
| US11773106 | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
17 Oct, 2036
(11 years from now)
| Active |
| US11780847 | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof |
17 Oct, 2036
(11 years from now)
| Active |
| US11780848 | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof |
17 Oct, 2036
(11 years from now)
| Active |
| US11787815 | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
17 Oct, 2036
(11 years from now)
| Active |
| US11795175 | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
17 Oct, 2036
(11 years from now)
| Active |
| US11976077 | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-α]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms therof |
17 Oct, 2036
(11 years from now)
| Active |
| US11993605 | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
17 Oct, 2036
(11 years from now)
| Active |
| US11993606 | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
17 Oct, 2036
(11 years from now)
| Active |
| US12077545 | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
17 Oct, 2036
(11 years from now)
| Active |
| US12091415 | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
17 Oct, 2036
(11 years from now)
| Active |
| US12103933 | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
17 Oct, 2036
(11 years from now)
| Active |
| US12110297 | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
17 Oct, 2036
(11 years from now)
| Active |
| US12110298 | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
17 Oct, 2036
(11 years from now)
| Active |
| US12116373 | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
17 Oct, 2036
(11 years from now)
| Active |
| US12134621 | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
17 Oct, 2036
(11 years from now)
| Active |
| US9951080 | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-alpha]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
17 Oct, 2036
(11 years from now)
| Active |
| US9963459 | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-alpla]pyrrolo[2,3-e]-pyrazin-8-YL)-N-(2,2,2-Trifluoroethyl)pyrrol and solid state forms thereof |
17 Oct, 2036
(11 years from now)
| Active |
| USRE47221 | Tricyclic compounds |
16 Aug, 2033
(8 years from now)
| Active |
| US8962629 | Tricyclic compounds |
15 Jan, 2031
(5 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Rinvoq's drug page
50. Rinvoq Lq
Rinvoq Lq is protected by 10 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10981923 | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[l,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
17 Oct, 2036
(11 years from now)
| Active |
| US11186584 | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
17 Oct, 2036
(11 years from now)
| Active |
| US11661425 | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
17 Oct, 2036
(11 years from now)
| Active |
| US11680069 | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
17 Oct, 2036
(11 years from now)
| Active |
| US11718627 | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
17 Oct, 2036
(11 years from now)
| Active |
| US11773105 | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]- pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
17 Oct, 2036
(11 years from now)
| Active |
| US12110298 | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
17 Oct, 2036
(11 years from now)
| Active |
| US9951080 | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-alpha]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
17 Oct, 2036
(11 years from now)
| Active |
| USRE47221 | Tricyclic compounds |
16 Aug, 2033
(8 years from now)
| Active |
| US8962629 | Tricyclic compounds |
15 Jan, 2031
(5 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Rinvoq Lq's drug page
51. Savella
Savella is protected by 4 patents, out of which 3 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7994220 | Milnacipran for the long-term treatment of fibromyalgia syndrome |
19 Sep, 2029
(4 years from now)
| Active |
| US6602911 | Methods of treating fibromyalgia |
14 Jan, 2023
(2 years ago)
| Expired |
| US6992110 | Methods of treating fibromyalgia syndrome, chronic fatigue syndrome and pain |
05 Nov, 2021
(3 years ago)
| Expired |
| US7888342 | Methods of treating fibromyalgia syndrome, chronic fatigue syndrome and pain |
05 Nov, 2021
(3 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Savella's drug page
52. Simcor
Simcor is protected by 9 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6469035 | Methods of pretreating hyperlipidemic individuals with a flush inhibiting agent prior to the start of single daily dose nicotinic acid therapy to reduce flushing provoked by nicotinic acid |
15 Mar, 2018
(7 years ago)
| Expired |
| US6080428 | Nicotinic acid compositions for treating hyperlipidemia and related methods therefor |
27 May, 2017
(8 years ago)
| Expired |
| US6129930 | Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night |
20 Sep, 2013
(11 years ago)
| Expired |
| US6406715 | Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique urinary metabolite profiles |
20 Sep, 2013
(11 years ago)
| Expired |
| US6676967 | Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia |
20 Sep, 2013
(11 years ago)
| Expired |
| US6746691 | Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics |
20 Sep, 2013
(11 years ago)
| Expired |
| US6818229 | Intermediate release nicotinic acid compositions for treating hyperlipidemia |
20 Sep, 2013
(11 years ago)
| Expired |
| US7011848 | Hydrophobic component free sustained release nicotinic acid compositions for treating hyperlipidemia and related methods therefor |
20 Sep, 2013
(11 years ago)
| Expired |
| US7998506 | Nicotinic acid compositions for treating hyperlipidemia and related methods therefor |
20 Sep, 2013
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Simcor's drug page
53. Tarka
Tarka is protected by 1 patent, which has expired already. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5721244 | Combination of angiotensin-converting enzyme inhibitors with calcium antagonists as well as their use in drugs |
24 Feb, 2015
(10 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Tarka's drug page
54. Technivie
Technivie is protected by 19 patents, out of which 12 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8691938 | Anti-viral compounds |
13 Apr, 2032
(6 years from now)
| Active |
| US8420596
(Pediatric)
| Macrocyclic hepatitis C serine protease inhibitors |
10 Oct, 2031
(6 years from now)
| Active |
| US8686026 | Solid compositions |
09 Jun, 2031
(5 years from now)
| Active |
| US8420596 | Macrocyclic hepatitis C serine protease inhibitors |
10 Apr, 2031
(5 years from now)
| Active |
| US9044480 | Compositions and methods for treating HCV |
10 Apr, 2031
(5 years from now)
| Active |
| US9006387 | Anti-viral compounds |
10 Jun, 2030
(4 years from now)
| Active |
| US8642538 | Macrocyclic hepatitis C serine protease inhibitors |
10 Sep, 2029
(4 years from now)
| Active |
| US8268349
(Pediatric)
| Solid pharmaceutical dosage form |
25 Feb, 2025
(4 months ago)
| Expired |
| US8399015
(Pediatric)
| Solid pharmaceutical dosage form |
25 Feb, 2025
(4 months ago)
| Expired |
| US8268349 | Solid pharmaceutical dosage form |
25 Aug, 2024
(10 months ago)
| Expired |
| US8399015 | Solid pharmaceutical dosage form |
25 Aug, 2024
(10 months ago)
| Expired |
| US7364752
(Pediatric)
| Solid dispersion pharamaceutical formulations |
10 May, 2021
(4 years ago)
| Expired |
| US7364752 | Solid dispersion pharamaceutical formulations |
10 Nov, 2020
(4 years ago)
| Expired |
| US7148359
(Pediatric)
| Polymorph of a pharmaceutical |
19 Jan, 2020
(5 years ago)
| Expired |
| US7148359 | Polymorph of a pharmaceutical |
19 Jul, 2019
(5 years ago)
| Expired |
| US6037157
(Pediatric)
| Method for improving pharmacokinetics |
26 Dec, 2016
(8 years ago)
| Expired |
| US6703403
(Pediatric)
| Method for improving pharmacokinetics |
26 Dec, 2016
(8 years ago)
| Expired |
| US6037157 | Method for improving pharmacokinetics |
26 Jun, 2016
(9 years ago)
| Expired |
| US6703403 | Method for improving pharmacokinetics |
26 Jun, 2016
(9 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Technivie's drug page
55. Teflaro
Teflaro is protected by 5 patents, out of which 3 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8247400 | Cephem compounds useful for the treatment of bacterial infections |
10 Feb, 2031
(5 years from now)
| Active |
| US9629861 | Compositions and methods for treating bacterial infections using ceftaroline |
21 Sep, 2030
(5 years from now)
| Active |
| US6906055 | Phosphonocephem compound |
15 Dec, 2021
(3 years ago)
| Expired |
| US7419973 | Phosphonocephem compound |
15 Dec, 2021
(3 years ago)
| Expired |
| US6417175 | Phosphonocephem derivatives, process for the preparation of the same, and use thereof |
17 Dec, 2018
(6 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Teflaro's drug page
56. Teveten
Teveten is protected by 1 patent, which has expired already. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5656650 | Angiotensin II receptor blocking compositions |
12 Aug, 2014
(10 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Teveten's drug page
57. Teveten Hct
Teveten Hct is protected by 1 patent, which has expired already. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5656650 | Angiotensin II receptor blocking compositions |
12 Aug, 2014
(10 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Teveten Hct's drug page
58. Tricor
Tricor is protected by 9 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7276249 | Nanoparticulate fibrate formulations |
21 Feb, 2023
(2 years ago)
| Expired |
| US7320802 | Methods of treatment using nanoparticulate fenofibrate compositions |
21 Feb, 2023
(2 years ago)
| Expired |
| US6375986 | Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate |
21 Sep, 2020
(4 years ago)
| Expired |
| US6074670 | Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it |
09 Jan, 2018
(7 years ago)
| Expired |
| US6277405 | Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it |
09 Jan, 2018
(7 years ago)
| Expired |
| US6589552 | Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it |
09 Jan, 2018
(7 years ago)
| Expired |
| US6652881 | Fenofibrate pharmaceutical composition having high bioavailability |
09 Jan, 2018
(7 years ago)
| Expired |
| US7037529 | Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it |
09 Jan, 2018
(7 years ago)
| Expired |
| US7041319 | Fenofibrate pharmaceutical composition having high bioavailabilty |
09 Jan, 2018
(7 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Tricor's drug page
59. Trilipix
Trilipix is protected by 1 patent, which has expired already. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7259186 | Salts of fenofibric acid and pharmaceutical formulations thereof |
07 Jan, 2025
(5 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Trilipix's drug page
60. Ubrelvy
Ubrelvy is protected by 12 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11717515 | Treatment of migraine |
22 Dec, 2041
(16 years from now)
| Active |
| US11857542 | Treatment of migraine |
22 Dec, 2041
(16 years from now)
| Active |
| US12070450 | Treatment of migraine |
22 Dec, 2041
(16 years from now)
| Active |
| US12194030 | Treatment of migraine |
22 Dec, 2041
(16 years from now)
| Active |
| US10117836 | Tablet formulation for CGRP active compounds |
30 Jan, 2035
(9 years from now)
| Active |
| US11925709 | Tablet formulation for CGRP active compounds |
30 Jan, 2035
(9 years from now)
| Active |
| US12168004 | Treatment of migraine |
30 Jan, 2035
(9 years from now)
| Active |
| US12220408 | Treatment of migraine |
30 Jan, 2035
(9 years from now)
| Active |
| US8912210 | Piperidinone carboxamide azaindane CGRP receptor antagonists |
23 Dec, 2033
(8 years from now)
| Active |
| US8754096 | Piperidinone carboxamide azaindane CGRP receptor antagonists |
19 Jul, 2032
(7 years from now)
| Active |
| US9499545 | Piperidinone carboxamide azaindane CGRP receptor antagonists |
10 Nov, 2031
(6 years from now)
| Active |
| US9833448 | Piperidinone carboxamide azaindane CGRP receptor antagonists |
10 Nov, 2031
(6 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Ubrelvy's drug page
61. Ultane
Ultane is protected by 8 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6074668
(Pediatric)
| Container for an inhalation anesthetic |
09 Jul, 2018
(6 years ago)
| Expired |
| US6074668 | Container for an inhalation anesthetic |
09 Jan, 2018
(7 years ago)
| Expired |
| US5990176
(Pediatric)
| Fluoroether compositions and methods for inhibiting their degradation in the presence of a Lewis acid |
27 Jul, 2017
(7 years ago)
| Expired |
| US6288127
(Pediatric)
| Fluoroether compositions and methods for inhibiting their degradation in the presence of a Lewis acid |
27 Jul, 2017
(7 years ago)
| Expired |
| US6444859
(Pediatric)
| Fluoroether compositions and methods for inhibiting their degradation in the presence of a Lewis acid |
27 Jul, 2017
(7 years ago)
| Expired |
| US5990176 | Fluoroether compositions and methods for inhibiting their degradation in the presence of a Lewis acid |
27 Jan, 2017
(8 years ago)
| Expired |
| US6288127 | Fluoroether compositions and methods for inhibiting their degradation in the presence of a Lewis acid |
27 Jan, 2017
(8 years ago)
| Expired |
| US6444859 | Fluoroether compositions and methods for inhibiting their degradation in the presence of a Lewis acid |
27 Jan, 2017
(8 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Ultane's drug page
62. Vaniqa
Vaniqa is protected by 1 patent, which has expired already. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5648394 | Topical composition for inhibiting hair growth |
15 Jul, 2014
(10 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Vaniqa's drug page
63. Venclexta
Venclexta is protected by 10 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10993942 | Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitor |
06 Sep, 2033
(8 years from now)
| Active |
| US11110087 | Combination therapy of a type II anti-CD20 antibody with a selective Bcl-2 inhibitor |
06 Sep, 2033
(8 years from now)
| Active |
| US11413282 | Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitor |
06 Sep, 2033
(8 years from now)
| Active |
| US11590128 | Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitor |
06 Sep, 2033
(8 years from now)
| Active |
| US9539251 | Combination therapy of a type II anti-CD20 antibody with a selective Bcl-2 inhibitor |
06 Sep, 2033
(8 years from now)
| Active |
| US11369599 | Melt-extruded solid dispersions containing an apoptosis-inducing agent |
23 May, 2032
(6 years from now)
| Active |
| US8722657 | Salts and crystalline forms of an apoptosis-inducing agent |
29 Jan, 2032
(6 years from now)
| Active |
| US10730873 | Salts and crystalline forms of an apoptosis-inducing agent |
21 Nov, 2031
(6 years from now)
| Active |
| US8546399 | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
27 Jun, 2031
(5 years from now)
| Active |
| US9174982 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
26 May, 2030
(4 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Venclexta's drug page
64. Viberzi
Viberzi is protected by 21 patents, out of which 7 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10188632 | Opioid receptor modulator dosage formulations |
14 Mar, 2033
(7 years from now)
| Active |
| US11007179 | Opioid receptor modulator dosage formulations |
14 Mar, 2033
(7 years from now)
| Active |
| US11090291 | Opioid receptor modulator dosage formulations |
14 Mar, 2033
(7 years from now)
| Active |
| US11160792 | Opioid receptor modulator dosage formulations |
14 Mar, 2033
(7 years from now)
| Active |
| US11229627 | Opioid receptor modulator dosage formulations |
14 Mar, 2033
(7 years from now)
| Active |
| US11311516 | Opioid receptor modulator dosage formulations |
14 Mar, 2033
(7 years from now)
| Active |
| US11484527 | Opioid receptor modulator dosage formulations |
14 Mar, 2033
(7 years from now)
| Active |
| US12097187 | Opioid receptor modulator dosage formulations |
14 Mar, 2033
(7 years from now)
| Active |
| US9675587 | Opioid receptor modulator dosage formulations |
14 Mar, 2033
(7 years from now)
| Active |
| US7741356 | Compounds as opioid receptor modulators |
27 May, 2029
(3 years from now)
| Active |
| US8691860 | Crystals and process of making 5-({(2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(-4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid |
07 Jul, 2028
(3 years from now)
| Active |
| US9115091 | Crystals and process of making 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl—1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid |
07 Jul, 2028
(3 years from now)
| Active |
| US9364489 | Crystals and process of making 5-({[2-amino-3-(4-Carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid |
07 Jul, 2028
(3 years from now)
| Active |
| US9789125 | Crystals and process of making 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid |
07 Jul, 2028
(3 years from now)
| Active |
| US10213415 | Compounds as opioid receptor modulators |
14 Mar, 2025
(3 months ago)
| Expired |
| US7786158 | Compounds as opioid receptor modulators |
14 Mar, 2025
(3 months ago)
| Expired |
| US8344011 | Compounds as opioid receptor modulators |
14 Mar, 2025
(3 months ago)
| Expired |
| US8609709 | Compounds as opioid receptor modulators |
14 Mar, 2025
(3 months ago)
| Expired |
| US8772325 | Compounds as opioid receptor modulators |
14 Mar, 2025
(3 months ago)
| Expired |
| US9205076 | Compounds as opioid receptor modulators |
14 Mar, 2025
(3 months ago)
| Expired |
| US9700542 | Compounds as opioid receptor modulators |
14 Mar, 2025
(3 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Viberzi's drug page
65. Vicoprofen
Vicoprofen is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6348216 | Ibuprofen and narcotic analgesic compositions |
10 Jun, 2017
(8 years ago)
| Expired |
| US6599531 | Method of making ibuprofen and narcotic analgesic compositions |
10 Jun, 2017
(8 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Vicoprofen's drug page
66. Viekira Pak (copackaged)
Viekira Pak (copackaged) is protected by 21 patents, out of which 6 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10201542 | Formulations of pyrimidinedione derivative compounds |
18 Oct, 2033
(8 years from now)
| Active |
| US9629841 | Formulations of pyrimidinedione derivative compounds |
18 Oct, 2033
(8 years from now)
| Active |
| US8466159 | Methods for treating HCV |
04 Sep, 2032
(7 years from now)
| Active |
| US8492386 | Methods for treating HCV |
04 Sep, 2032
(7 years from now)
| Active |
| US8680106 | Methods for treating HCV |
04 Sep, 2032
(7 years from now)
| Active |
| US8685984 | Methods for treating HCV |
04 Sep, 2032
(7 years from now)
| Active |
| US8691938 | Anti-viral compounds |
13 Apr, 2032
(6 years from now)
| Active |
| US8686026 | Solid compositions |
09 Jun, 2031
(5 years from now)
| Active |
| US8420596 | Macrocyclic hepatitis C serine protease inhibitors |
10 Apr, 2031
(5 years from now)
| Active |
| US9044480 | Compositions and methods for treating HCV |
10 Apr, 2031
(5 years from now)
| Active |
| US9006387 | Anti-viral compounds |
10 Jun, 2030
(4 years from now)
| Active |
| US8642538 | Macrocyclic hepatitis C serine protease inhibitors |
10 Sep, 2029
(4 years from now)
| Active |
| US8188104 | Anti-infective agents and uses thereof |
17 May, 2029
(3 years from now)
| Active |
| US8501238 | Anti-infective agents and uses thereof |
19 Dec, 2028
(3 years from now)
| Active |
| US9139536 | Anti-infective agents and uses thereof |
09 Nov, 2028
(3 years from now)
| Active |
| US8268349 | Solid pharmaceutical dosage form |
25 Aug, 2024
(10 months ago)
| Expired |
| US8399015 | Solid pharmaceutical dosage form |
25 Aug, 2024
(10 months ago)
| Expired |
| US7364752 | Solid dispersion pharamaceutical formulations |
10 Nov, 2020
(4 years ago)
| Expired |
| US7148359 | Polymorph of a pharmaceutical |
19 Jul, 2019
(5 years ago)
| Expired |
| US6037157 | Method for improving pharmacokinetics |
26 Jun, 2016
(9 years ago)
| Expired |
| US6703403 | Method for improving pharmacokinetics |
26 Jun, 2016
(9 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Viekira Pak (copackaged)'s drug page
67. Viekira Xr
Viekira Xr is protected by 22 patents, out of which 4 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10105365 | Solid antiviral dosage forms |
02 Jan, 2035
(9 years from now)
| Active |
| US9333204 | Solid antiviral dosage forms |
02 Jan, 2035
(9 years from now)
| Active |
| US9744170 | Solid antiviral dosage forms |
02 Jan, 2035
(9 years from now)
| Active |
| US8466159 | Methods for treating HCV |
04 Sep, 2032
(7 years from now)
| Active |
| US8492386 | Methods for treating HCV |
04 Sep, 2032
(7 years from now)
| Active |
| US8680106 | Methods for treating HCV |
04 Sep, 2032
(7 years from now)
| Active |
| US8685984 | Methods for treating HCV |
04 Sep, 2032
(7 years from now)
| Active |
| US10201541 | Compositions and methods for treating HCV |
17 May, 2032
(6 years from now)
| Active |
| US10201584 | Compositions and methods for treating HCV |
17 May, 2032
(6 years from now)
| Active |
| US8691938 | Anti-viral compounds |
13 Apr, 2032
(6 years from now)
| Active |
| US8686026 | Solid compositions |
09 Jun, 2031
(5 years from now)
| Active |
| US8420596 | Macrocyclic hepatitis C serine protease inhibitors |
10 Apr, 2031
(5 years from now)
| Active |
| US9044480 | Compositions and methods for treating HCV |
10 Apr, 2031
(5 years from now)
| Active |
| US9006387 | Anti-viral compounds |
10 Jun, 2030
(4 years from now)
| Active |
| US8642538 | Macrocyclic hepatitis C serine protease inhibitors |
10 Sep, 2029
(4 years from now)
| Active |
| US8188104 | Anti-infective agents and uses thereof |
17 May, 2029
(3 years from now)
| Active |
| US9139536 | Anti-infective agents and uses thereof |
09 Nov, 2028
(3 years from now)
| Active |
| US8501238 | Anti-infective agents and uses thereof |
17 Sep, 2028
(3 years from now)
| Active |
| US8268349 | Solid pharmaceutical dosage form |
25 Aug, 2024
(10 months ago)
| Expired |
| US8399015 | Solid pharmaceutical dosage form |
25 Aug, 2024
(10 months ago)
| Expired |
| US7364752 | Solid dispersion pharamaceutical formulations |
10 Nov, 2020
(4 years ago)
| Expired |
| US7148359 | Polymorph of a pharmaceutical |
19 Jul, 2019
(5 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Viekira Xr's drug page
68. Viibryd
Viibryd is protected by 9 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7834020
(Pediatric)
| Polymorphic forms of 1-′4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride |
05 Dec, 2022
(2 years ago)
| Expired |
| US8193195
(Pediatric)
| Polymorphic forms of 1-'4-(5-cyanoindol-3-yl) butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride |
05 Dec, 2022
(2 years ago)
| Expired |
| US8236804
(Pediatric)
| Polymorphic forms of 1-′4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride |
05 Dec, 2022
(2 years ago)
| Expired |
| US8673921
(Pediatric)
| Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride |
05 Dec, 2022
(2 years ago)
| Expired |
| US7834020 | Polymorphic forms of 1-′4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride |
05 Jun, 2022
(3 years ago)
| Expired |
| US8193195 | Polymorphic forms of 1-'4-(5-cyanoindol-3-yl) butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride |
05 Jun, 2022
(3 years ago)
| Expired |
| US8236804 | Polymorphic forms of 1-′4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride |
05 Jun, 2022
(3 years ago)
| Expired |
| US8673921 | Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride |
05 Jun, 2022
(3 years ago)
| Expired |
| US5532241 | Piperidines and piperazines |
29 Sep, 2014
(10 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Viibryd's drug page
69. Vraylar
Vraylar is protected by 5 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7737142 | (Thio) carbamoyl-cyclohexane derivatives as D3/D2 receptor antagonists |
17 Sep, 2029
(4 years from now)
| Active |
| USRE47350 | Pharmaceutical formulations containing dopamine receptor ligands |
16 Jul, 2029
(4 years from now)
| Active |
| USRE49110 | Pharmaceutical formulations containing dopamine receptor ligands |
16 Jul, 2029
(4 years from now)
| Active |
| USRE49302 | Pharmaceutical formulations containing dopamine receptor ligands |
16 Jul, 2029
(4 years from now)
| Active |
| US7943621 | Salts of piperazine compounds as D3/D2 antagonists |
16 Dec, 2028
(3 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Vraylar's drug page
70. Vuity
Vuity is protected by 2 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10610518 | Presbyopia treatments |
24 Apr, 2039
(13 years from now)
| Active |
| US11285134 | Presbyopia treatments |
24 Apr, 2039
(13 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Vuity's drug page
71. Vyalev
Vyalev is protected by 4 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12251365 | Pharmaceutical formulations for subcutaneous administration |
10 Jun, 2040
(14 years from now)
| Active |
| US10174061 | Carbidopa and L-dopa prodrugs and methods of use |
21 Oct, 2035
(10 years from now)
| Active |
| US10730895 | Carbidopa prodrug |
21 Oct, 2035
(10 years from now)
| Active |
| US9446059 | Carbidopa and L-dopa prodrugs and methods of use |
21 Oct, 2035
(10 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Vyalev's drug page
72. Zemplar
Zemplar is protected by 9 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6136799
(Pediatric)
| Cosolvent formulations |
08 Oct, 2018
(6 years ago)
| Expired |
| US6361758
(Pediatric)
| Cosolvent formulations |
08 Oct, 2018
(6 years ago)
| Expired |
| US6136799 | Cosolvent formulations |
08 Apr, 2018
(7 years ago)
| Expired |
| US6361758 | Cosolvent formulations |
08 Apr, 2018
(7 years ago)
| Expired |
| US5597815
(Pediatric)
| Prevention of hyperphosphatemia in kidney disorder patients |
13 Jan, 2016
(9 years ago)
| Expired |
| US5597815 | Prevention of hyperphosphatemia in kidney disorder patients |
13 Jul, 2015
(9 years ago)
| Expired |
| US5587497
(Pediatric)
| 19-nor-vitamin D compounds |
24 Jun, 2014
(11 years ago)
| Expired |
| US5587497 | 19-nor-vitamin D compounds |
24 Dec, 2013
(11 years ago)
| Expired |
| US5246925
(Pediatric)
| 19-nor-vitamin D compounds for use in treating hyperparathyroidism |
17 Oct, 2012
(12 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Zemplar's drug page
73. Zymaxid
Zymaxid is protected by 4 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6333045
(Pediatric)
| Aqueous liquid pharmaceutical composition comprised of gatifloxacin |
20 Feb, 2020
(5 years ago)
| Expired |
| US6333045 | Aqueous liquid pharmaceutical composition comprised of gatifloxacin |
20 Aug, 2019
(5 years ago)
| Expired |
| US5880283
(Pediatric)
| 8-alkoxyquinolonecarboxylic acid hydrate with excellent stability and process for producing the same |
05 Jun, 2016
(9 years ago)
| Expired |
| US5880283 | 8-alkoxyquinolonecarboxylic acid hydrate with excellent stability and process for producing the same |
05 Dec, 2015
(9 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Zymaxid's drug page